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ABSTRACT 
Non-small cell lung cancer (NSCLC) originates in the epithelia of the lung 
and persists as the leading cause of cancer-related death in the United States. 
Many studies have shown that hypoxia is prevalent in NSCLC tissue and 
negatively influences treatment outcome.  
In previous studies, we investigated the efficacy of γ-secretase inhibitor 
(GSI) treatment in an orthotopic mouse NSCLC model. Analysis of hypoxic areas 
of tumors from GSI treated animals showed reappearance of 4E-BP1 
phosphorylation at threonine 37/46 residues (T37/46). 4E-BP1 phosphorylation is 
primarily mediated by mechanistic target of rapamycin complex 1 (mTORC-1), a 
major cell integrator of growth factors stimulation, nutrient availability, and 
environmental cues.  
In this study, we sought to identify a putative target of γ-secretase that 
could mediate this apparent reactivation of mTORC-1 activity in otherwise 
quiescent hypoxic NSCLC. We identified amyloid precursor protein (APP) as the 
substrate of γ-secretase that mediates this anabolic reactivation upon GSI 
treatment. APP is a highly pleiotropic protein implicated in a plethora of cellular 
functions, including malignant growth. siRNA-mediated depletion of APP in 
NSCLC cell lines cultured in hypoxia enhanced 4E-BP1’s phosphorylation at 
T37/46. 
xv 
 
 
 
Our results indicated that depletion of APP caused 4E-BP1 
phosphorylation pattern rearrangement by affecting various proteins including 
ERKs and the pseudophosphatase STYX, a novel APP target. Additionally, APP 
altered the recruitment of eIF4A RNA helicase to the translation initiation 
complex. These changes coincided with a prominent increase in the global 
protein synthesis rate.  
Since cell growth and division are inherently linked processes in both 
normal and cancerous cells, we investigated if depletion of APP had any effect 
on cell proliferation. Surprisingly, APP depletion resulted in a cyclin C-dependent 
G0 arrest of hypoxic NSCLC cells. This paradoxical uncoupling of cell growth and 
proliferation caused cellular abnormalities, including increased cell size and 
necrotic cell death. The observed changes were reversed by the overexpression 
of APP intracellular domain (AICD). 
In conclusion, APP (via AICD) seems to mediate G0/G1 transitions and 
moderate cell growth rate. As inhibition of APP causes cell cycle arrest and 
necrosis, we propose that APP could be a novel therapeutic target for the 
eradication of hypoxic NSCLC. 
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CHAPTER ONE 
INTRODUCTION 
 
Novel approaches to target hypoxic non-small cell lung cancer (NSCLC) 
cells are urgently needed to improve the treatment of this deadly disease. 
NSCLC is the leading cause of cancer-related deaths in the US in both men and 
women, while low oxygen concentration, or hypoxia, was shown to confer re-
sistance to radiotherapy or chemotherapy, promote tumor progression, provide a 
niche for cancer stem cells (CSC), and is linked to poor prognosis (Walsh et al., 
2014; American Cancer Society, 2015). 
 
LUNG CANCER 
 
In the Western world, lung cancer is the leading cause of cancer-related 
deaths (Esposito et al., 2010).  Projections for 2015 indicate that more people will 
die of lung cancer than of breast, prostate, and colorectal cancers combined 
(American Lung Association, 2015). The overall five-year survival rate of lung 
cancer patients is about 15% (all stages, American Lung Association, 2015). 
Age-adjusted death rate of lung cancer is higher in males than females.  
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It is also higher for black men compared to white men while the rates are the 
same for both black and white women (Centers for Disease Control and Preven-
tion, 2014). Lung cancer is broadly subdivided into two major histologic subtypes: 
small cell lung cancer (SCLC) and non-small cell lung cancers (NSCLC). NSCLC 
is of epithelial origin and is considered less responsive to chemotherapy as com-
pared to SCLC (Vescio et al., 1990). Although SCLC, which is of neuroendocrine 
origin, responds well to traditional cytotoxic therapies, it recurs quickly as chemo-
therapy-resistant. In this form, SCLC rapidly spreads to the entire chest and me-
tastasizes very quickly. These features make SCLC one of the most aggressive 
known malignancies with a median survival after diagnosis of 11.8 months (Ba-
bakoohi et al., 2012). 70% of NSCLC cases are diagnosed at advanced stages 
(IIIB and IV). In these conditions, the five-year survival of NSCLC patients is 
about 2% (Govindan et al., 2006; Krug et al., 2008). 
 
Non-small cell lung cancer: Histology 
 
Approximately 85% of all lung cancer cases are NSCLC (National Cancer 
Institute, 2014). Although recently reclassified, NSCLC is traditionally subdivided 
into three main subtypes: adenocarcinoma of the lung (ACL), squamous cell car-
cinoma (SCC), and large cell carcinoma (LCC). ACL, SCC, and LCC account for 
40%, 25%, and 10% of lung cancer cases, respectively (National Cancer Institute, 
2013).  
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The distinctive features of lung adenocarcinomas include histologic heter-
ogeneity, glandular differentiation, and mucin production. These tumors are a 
mixture of different patterns including acinar, papillary, micropapillary, and bron-
chioloalveolar (Travis et al., 2011). On the other hand, a key characteristic of 
squamous cell carcinoma is evidence of keratinization, including either intercellu-
lar bridges or squamous “keratin pearls” (Heighway and Betticher, 2004). Some 
lung tumors are poorly differentiated and cannot be classified as SCLC, ACL or 
SSC. If histological examination of these tumors shows no apparent features of 
squamous cells, neuroendocrine cells, columnar epithelium, and shows no signs 
of mucin secretion, then these tumors may be diagnosed as LCCs. Basically, 
LCC is a diagnosis of exclusion; the cells are not small, but they do not present a 
glandular-like organization or a squamous phenotype. Different variants of LCCs 
include clear cell carcinomas, large cell carcinomas with rhabdoid phenotype, 
and lymphoepithelioma-like carcinomas (Heighway and Betticher, 2004; National 
Cancer Institute, 2014). 
ACL and LCC are located in peripheral areas of the lungs, while SCC typi-
cally arises in proximal bronchi (Schrump et al., 2008). Different localization indi-
cates that these NSCLC subtypes may originate from distinct progenitor cells 
(Galluzzo and Bocchetta, 2011).  
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Cellular origin 
 
Although the lung does not undergo a constant renewal of its epithelia, it 
can repair damage, even significant damage. Each lung compartment contains a 
limited number of progenitor cells that can undergo injury-induced proliferation 
and initiate the repopulation of the damaged areas. The multipotent progenitor 
cells located within the bronchial epithelium include cytokeratin 14-expressing 
basal cells and naphthalene-resistant Clara cell secretory protein (CCSP)-
expressing cells (CE). Both cell populations appear necessary for the renewal of 
the bronchiolar epithelium upon injury (Wistuba et al., 1997; Hong et al., 2004). 
Most likely, these cells give rise to SCC, which generally originates in bronchi 
(Galluzzo and Bocchetta, 2011). ACL, which arises at the periphery of the lung, 
has been demonstrated to originate from progenitor cells localized to the bron-
chio-alveolar duct junctions (BADJ) (Giangreco et al., 2002). These bronchio-
alveolar stem cells (BASCs) initiate renewal of damaged alveolar epithelium. 
BASCs are positive for prosurfactant apoprotein-C (SP-C), a T2 pneumocyte 
marker, and CCSP, a marker of Clara cells. In vivo studies indicate that BACSs 
genetically engineered with CRE-recombinase inducible oncogenes give rise to 
adenomas and adenocarcinomas, which are indistinguishable from human ACL 
(Kim et al., 2015). While the identity of LCC progenitor cells is still debated, ex-
perts in the field seem to agree that this malignancy can originate from BASCs 
(Hanna and Onaitis, 2013). 
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Etiology 
 
90% of lung cancer deaths are due to active smoking (American Lung As-
sociation, 2015). At least 70 different chemicals present in cigarette smoke have 
been demonstrated to be carcinogenic (The United States Department of Health 
and Human Services, 2010). Some of the most harmful, cancer-causing chemi-
cals include nicotine-derived nitrosamine ketone (NNK) and DNA damaging pol-
yaromatic hydrocarbons (PAH; Schrump et al., 2008). Cigarette-associated car-
cinogens were shown to activate various pro-survival signaling pathways includ-
ing AKT and ERK, and to induce mutations within tumor suppressor genes like 
p53 (Belinsky et al., 1996; Tsurutani et al., 2005). Importantly, the risk of lung 
cancer depends on the duration and intensity of smoking, decreasing gradually 
after smoking cessation (Peto et al., 2000).  
The role of genetic predisposition to lung cancer is still not clear. Nonethe-
less, some studies reported an association between polymorphisms involving 
several genes, such as ERCC2/XPD and CHRNA3, and lung cancer risk (Zhan 
et al., 2010; Xiao et al., 2014).  
Environmental pollutants are increasingly implicated in NSCLC pathogen-
esis. Traditional environmental agents that are unequivocally considered to 
cause NSCLC are radon, certain types of coal, and asbestos (American Lung 
Association, 2015). Increasingly, the scientific community is considering other 
factors such as ground transportation or exhaust fumes as alternative causes of 
NSCLC (Pope et al., 1995; Larkin, 2000). 
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Numerous molecular driver mutations have been identified in NSCLC, and 
the best-identified examples are found in the most common histopathological 
type of NSCLC, adenocarcinoma. These include mutations of well-known onco-
genes, such as KRAS, NRAS, ALK, MET, EGFR, PIK3CA, AKT1, BRAF, HER2, 
MEK1, RET, and ROS1. Tumor suppressor genes commonly lost in NSCLC in-
clude p16, p53, PTEN, and others (Schrump et al., 2008; Lovly et al., 2015). 
Some of these mutations can predict treatment outcomes. For example, specific 
EGFR mutations render some NSCLC sensitive to drugs such as erlotinib and 
gefitinib (Gazdar, 2009). However, no single mutation alone seems to represent 
a good indicator of prognosis (Schrump et al., 2008; Jackman et al., 2010). 
 
Diagnosis and treatment approaches 
 
About 70% of NSCLC cases are diagnosed at the stages IIIb and IV, in-
volving regional (lymph nodes) and distant (mainly bone, liver, adrenals) metas-
tasis (American Lung Association, 2015). The classic staging system used in 
NSCLC is called the Tumor (T, or primary tumor size and extent), Node (N, or 
lymph nodes involvement), Metastasis (M, or presence of distant metastases). 
This system is commonly referred as TNM Staging system and is summarized in 
Table 1 (refer to a table below; Schrump et al., 2008). 
Since most of the NSCLC cases are diagnosed at advanced stage, there 
is an urgent need for early detection methods (National Cancer Institute, 2014). 
Some of the approaches, such as sputum cytology or chest x-rays, were evalu-
7 
 
	  
ated in the past, but were found to be ineffective for early detection of lung can-
cers (Schrump et al., 2008). Others, like low-dose helical computed tomography 
(CT) scans, are still evaluated (National Lung Screening Trial Research Team, 
2011). 
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Table 1. Tumor, node, metastasis (TNM) staging system. The standard sys-
tem used to stage NSCLC cases and assess the characteristics of primary tumor, 
but also proximal (nodal) and distant (other organs) metastasis. Modified from 
Schrump et al., 2008 
 
 DESCRIPTION 
PRIMARY TUMOR  
TX Main tumor cannot be measured 
T0 No main tumor 
T1-T4 Size and/or extent of the main tumor  
(Higher number corresponds to larger size or 
infiltration to nearby tissue). Example: T1 is a 
primary tumor of no more than 3 cm in diame-
ter that does not infiltrate the pericardium, or 
the peritoneum.  
REGIONAL 
LYMPH NODE 
INVOLVEMENT 
 
NX Nodal involvement cannot be measured 
N0 No nodal involvement 
N1-N3 Number and location of lymph nodes that 
contain cancer  
(The more distal the node is from the primary 
tumor, the higher the “N” number) 
METASTATIC 
INVOLEVMENT 
 
MX Metastases cannot be measured 
M0 No metastases 
M1 Metastases present (regardless of the size 
and location of the metastasis) 
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Currently, the standard of care for treatment of NSCLC patients is a com-
bination of cytotoxic platinum based compounds, like cisplatin or carboplatin, and 
third-generation antineoplastic agents, including gemcitabine (a nucleoside ana-
log) and paclitaxel (an inhibitor of mitosis; Rowinsky and Donehower, 1995; 
Schiller et al., 2002). The major disadvantage of these compounds is limited effi-
cacy and high toxicity, which is a common health concern especially in elderly 
patients (Florea and Büsselberg, 2011). A new treatment approach is to target 
pathways that are essential for cancer cell survival, growth, metastasis, etc. One 
example is bevacizumab (inhibitor of vascular endothelial growth factor A), which 
is the only anti-angiogenic agent approved to use as the first-line therapy for ad-
vanced non-squamous NSCLC (Reck et al., 2009). However, bevacizumab 
treatment can only add about one month to the overall survival of NSCLC pa-
tients (Sandler et al., 2006; Lima et al., 2011). Other treatments, using EGFR and 
ALK inhibitors (erlotinib and crizotinib respectively) lead to resistance and tumor 
recurrence (Jackman et al., 2010; Doebele et al., 2012). Development of new 
drugs to target the underlying mechanisms of drug resistance is under investiga-
tion. Thus, new treatment strategies and molecular targets are urgently needed 
to improve the survival chances of NSCLC patients.  
As for all solid tumors, the hypoxic tumor microenvironment represents the 
major obstacle for therapy. This is due to a number of features that characterize 
hypoxic NSCLC, which will be detailed in the next chapter. 
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TUMOR HYPOXIA 
 
Hypoxic or low-oxygenated tumor microenvironment has been long recog-
nized as a major obstacle for cancer therapy (Harrison et al., 2002). Even though 
the tumor responds to oxygen and nutrients deficits by inducing neoangiogenesis 
in surrounding tissues, this process is inefficient, abnormal, and unable to meet 
the oxygen demands of cancer cells (Liu et al., 1995). As the tumor grows, the 
distance between cancer cells and blood vessels increases and some cancer 
cells will inevitably have limited access to nutrients and oxygen (Figure 1). 
Importantly, delivery of anticancer chemotheraputics to these distant tumor cells 
is also reduced, contributing to treatment resistance of hypoxic tumor tissue. 
Hypoxia regulates metabolic activity and proliferative potential of tumor cells. 
Cancer cells in a hypoxic microenvironment are under a metabolic checkpoint, 
mediated by the inhibition of cell growth regulator the mechanistic target of 
rapamycin complex 1 (mTORC-1) (see below). Cells within the hypoxic tumor 
mass are also quiescent (Busk and Horsman, 2013).  
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Figure 1. Tumor hypoxia. The microenvironment of solid tumors depends on 
their proximity to blood vessels. Areas in sufficient proximity to an arteriole have 
plenty of oxygen, nutrients, and buffering capability of human plasma. These 
cells are likely to proliferate and grow rapidly. The more distal tumor cells are to 
blood supply, the less anabolic and proliferative activities will be favored. In criti-
cal regions, oxygen, nutrients, and extracellular pH will no longer support growth 
or proliferation. These cells are quiescent and actively undergoing autophagy 
(green in the figure). If this situation is not ameliorated by increased blood flow to 
these areas, cancer cells will exhaust energy and undergo necrosis. This gradi-
ent of solutes distribution also applies to anticancer drugs. Modified from the 
OMCCCD website.   
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Hypoxia negatively influences both radiotherapy and chemotherapy. Lack 
of oxygen decreases the formation of DNA breaks mediated by ionizing radiation-
induced oxidative radicals (Grey et al., 1953). It also increases resistance of cells 
to antibiotics that also induce DNA breaks, like bleomycin (Hahn, 1996). Hypoxia 
causes cell growth arrest, thus rendering cancer cells resistant to cell cycle se-
lective chemotherapeutics, such as 5-fluorouracil (Goda et al., 2003). Cancer 
cells improve their chances of survival in hypoxic microenvironment by increasing 
resistance to apoptotic cell death using a variety of mechanisms. Thus, these 
cancer cells also become resistant to apoptosis promoting agents, like Etoposide 
(Hussein et al., 2006). Hypoxia is also known to promote epithelial-to-
mesenchymal transition, thus increasing cancer invasiveness and metastasis 
(Pennacchietti et al., 2003; Hill et al., 2009; Chang et al., 2011). Because of 
profound alterations of the extracellular environment, hypoxic tumor tissue 
interferes with the activities of both the innate and acquired immune systems 
(Yotnda et al., 2010). Thus, hypoxia emerges as an important pro-survival factor 
that not only protects cancer cells from anti-cancer therapy but also favors a 
more aggressive phenotype. Not surprisingly, hypoxia is a well-recognized poor 
prognostic factor for cancer patients. 
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Molecular basis of tumor hypoxia 
 
Hypoxia affects the biology of cancer cells by inducing changes in their 
gene expression pattern. These changes are mediated by the master 
transcriptional regulators Hypoxia Inducible Factors (HIFs). HIFs can bind to the 
promoters or enhancers of a wide variety of target genes encoding proteins 
essential for cell growth, cell proliferation/survival, metabolism, and angiogenesis 
(Table 2). Two closely related proteins, HIF-1 and HIF-2, were shown to possess 
endogenous transactivation activity, while HIF-3 acts as a dominant-negative 
regulator of HIF-1 (Makino et al., 2001). HIF-1 is an extensively studied, major 
regulator of the transition between normoxia and hypoxia (Semenza et al., 1998). 
HIF-1 consists of hypoxia inducible subunit α and a constitutively expressed 
subunit β (also known as aryl hydrocarbon receptor nuclear translocator, or 
ARNT). In normoxia HIF-1α is transcribed and expressed but rapidly degraded 
(Wang et al., 1995). The signal for degradation includes a hydroxylation of two 
proline residues and acetylation of a lysine residue within the oxygen-dependent 
degradation domain (ODDD). This is followed by the recruitment of the von 
Hippel-Lindau E3 ubiquitin ligase complex and subsequent polyubiquitination of 
HIF-1α. This polyubiquitination targets HIF-1α for 26S proteasome-mediated 
degradation (Masson et al., 2001). Additionally, hydroxylation of an asparagine 
residue within the C-terminal transactivation domain (C-TAD) inhibits the 
14 
 
	  
interaction of HIF-1α with a co-activator CBP/p300, thus inhibiting its 
transactivation activity (Lando et al., 2002).  
In hypoxia, the HIF-1α protein is stable; it translocates to the nucleus and 
associates with HIF-1β subunit. This complex binds the hypoxia response 
elements of target genes, recruits transcriptional co-activators, and consequently 
induces transcription (Lando et al., 2002). The list of HIF regulated genes is still 
growing and includes genes encoding regulators of glucose uptake and glycolytic 
enzymes (GLUT-1, PGK, ALDA) allowing cancer cells to adapt their metabolism 
to low oxygen concentration, genes related to angiogenesis (VEGF) promoting 
blood vessels growth, as well as genes increasing cancer aggressiveness and 
metastasis (CXCR4) (Semenza et al., 2003). Thus, HIF-1α not only helps cancer 
cells adopt to and survive in hypoxic environment but also promotes its 
progression.  
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Table 2. Examples of HIF targets, hypoxia regulated phenotypes, and drugs 
that target central signaling pathways governing such phenomena. HIFs 
regulate transcription of many genes responsible for a wide variety of cellular 
functions (Höckel et al., 2001; Schofield et al., 2004). Some examples of drugs 
that target these pathways are listed in this table. 
 
HIF’s Targets Signaling Pathway Inhibitors 
Vascular endothelial growth 
factor A, Vascular endotheli-
al growth factor receptor 1, 
plasminogen activator inhibi-
tor 1 
Angiogenesis Bevacizumab 
(Sandler et al., 
2006) 
Transferrin, Transferrin re-
ceptor 
Transport anti-TfR mAb 
(Hong et al., 2013) 
Chemokine receptor 
CXCR4, cMet 
Cell migration Plerixafor  
(Uy et al., 2012) 
Glucose transporter-1, 
Hexokinase-2, aldolase A 
Energy metabolism 3-Bromopyruvate 
(Jae et al., 2009) 
Insulin-like growth factor 2, 
Protransforming growth fac-
tor alpha 
Survival DX-2647  
(Dransfield et al., 
2010) 
Notch, Oct4, Nanog Stem cell homeostasis GSI  
(Olsauskas-Kuprys 
et al., 2013) 
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Hypoxia and cancer stem cells 
 
Hypoxia has been conclusively linked to stem cell status. Stem and 
progenitor cells are characterized by the induction of signaling pathways, which 
play pivotal roles during embryogenesis (e.g., Wnt, Hedgehog, Notch). Under 
hypoxia, there seems to be a central axis between Notch and Oct4. Notch 
receptors are well-established regulators of cell differentiation. Upon activation, 
Notch receptors are cleaved and produce an intracellular domain (ICN).  This 
ICN then translocates to the nucleus and has transcriptional activity. It has been 
demonstrated that hypoxia inhibits myogenic satellite cell and neuronal stem cell 
diffferentiation in a Notch-dependent manner (Gustafsson et al., 2005). HIF-1α 
was shown to be recruited to the promoters of the Notch target genes and to 
interact with ICN. The interaction between HIF-1α and Notch signaling seems to 
be required for the maintenance of stem cells in an undifferentiated state. 
Additionally, HIF-2α binds the promoter of Oct-4 and increases its expression 
and activity. Oct-4 is an essential transcriptional regulator of stem cell self-
renewal and maintenance. HIF-2α is thought to regulate stem cell identity via 
activation of Oct4 (Covello et al., 2006).  
The inhibition of differentiation by hypoxia has important implications in 
cancer biology. Among HIF regulated genes, we can mention ATP-binding 
cassette transporters (ABC transporters including MDR1 or Bcrp/ABCG2), which 
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are expressed by stem cells and associated with chemoresistance (Tai et al., 
2005; Comerford et al., 2002; Krishnamurthy et al., 2004).  
Cancer stem cells (CSC) are thought to sustain cancer growth. They can 
either self-renew or give rise to cells that form a particular cancer type. 
Unfortunately, many therapeutic regimens do not lead to the eradication of 
cancer initiating cells (identified by some as cancer stem cells). The nature of 
NSCLC CSC is only recently being defined. A handful of recent reports have 
identified some surface markers associated with NSCLC CSC, including CD133 
and CD44 (Alamgeer et al., 2013). Additionally, the expression and activity of the 
cytoplasmic enzyme aldehyde dehydrogenase (ALDH) was shown to correlate 
with stem-like characteristics in NSCLC cell lines (Alamgeer et al., 2013). These 
included the ability to self-renew, proliferate, and generate tumors in vivo (Jiang 
et al., 2009). The exclusion of membrane permeable dyes is attributed to the 
overexpression of ATP-binding transporters by stem-like cells (Bunting, 2002). 
Notably, a population of cells (“side population”, SP) that exclude a Hoechst 
33342 dye was recently identified in NSCLC cell lines and tumors (Ho et al., 
2007; Alamgeer et al., 2013). These cells were shown to possess stem-like 
characteristics, for example, the ability to regenerate SP and non-SP cell 
populations and resistance to multiple anti-cancer drugs (Ho et al., 2007). A 
recent study has indicated that inhibition of driver oncogenes (such as EGFR) in 
NSCLC enriches the population of ALDH+ cells that display stem cell-like 
properties. These cells seem dependent on Notch-3 signaling (Arasada et al., 
2014). In conclusion, stem or progenitor cell identity seems to be mediated by a 
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number of factors that are provided within their niches. Since the ground-
breaking study by Gustaffson et al., a wealth of data has been gathered estab-
lishing the link between hypoxia inducible factors (HIFs), Notch signaling, the 
maintenance of the undifferentiated state, and the survival of NSCLC under hy-
poxia (Gustafsson et al., 2005; Keith and Simon, 2007). 
 
NSCLC and hypoxia 
 
Different techniques have been used to assess hypoxic areas of NSCLC 
tumors. Some studies applied staining for hypoxia inducible markers like HIF-1α 
or its downstream target glucose-transporter 1 (GLUT-1) (used as a hypoxia 
marker in our study; Jackson et al., 2010). GLUT-1 is often considered a more 
direct method to visualize hypoxic areas than HIF-1α, and its expression was 
shown to correlate with poor prognosis in numerous tumors, including NSCLC 
(Younes et al., 1997; Furudoi et al., 2001; Kawamura et al., 2001; Kang et al., 
2002; Kunkel et al., 2003; Tohma et al., 2005). Tumor hypoxia can also be visu-
alized with non-invasive imaging techniques using radiolabeled tracers like [18F] 
fluoromisonidazole (FMISO)  (Ziemer et al., 2003). In different studies of NSCLC 
patients, hypoxia was shown to be a predictive marker for tumor recurrence and 
treatment outcome (Jackson et al., 2010). Positron emission tomography (PET) 
imaging using fludeoxyglucose (18F) of fifty-seven patients with NSCLC showed 
that the tracer distribution predicts the probability of postoperative recurrence of 
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these patients (Higashi et al., 2002). Another study, including fourteen patients 
with advanced NSCLC, showed that kinetics of FMISO as visualized by PET im-
aging is predictive of tumor recurrence after radiotherapy (Eschmann et al., 
2005). In conclusion, hypoxia is a major problem in the treatment of NSCLC. Hy-
poxic NSCLC is poorly accessible to both radiotherapy and chemotherapy. Hy-
poxic pockets are most likely sheltering NSCLC CSC. My central hypothesis is 
that any successful therapeutic approach for NSCLC must aim at the eradication 
of hypoxic NSCLC microenvironment. This task is rendered even more challeng-
ing because of the aforementioned metabolic checkpoint/quiescence of hypoxic 
NSCLC cells. The vast majority of anticancer agents currently used or under de-
velopment selectively target actively proliferating or metabolic active cells. These 
are exactly the antitheses of hypoxic NSCLC cells. One potentially novel strategy 
in targeting hypoxic NSCLC would be reactivating anabolic processes in dormant 
cells in an environment that cannot sustain these activities. These cells would 
rapidly exhaust their energy reserve and suffer a similar fate of cells in which the 
hypoxic condition cannot be relieved (necrotic cell death, see Figure 1). The cel-
lular central hub where growth factor stimulation, energy levels, and nutrient 
availability are sensed and translated into cell fate choices is mechanistic target 
of rapamycin (mTOR) complex 1, or mTORC-1. The inherent linkage between 
growth and proliferation is achieved at this level (Laplante and Sabatini, 2009; 
Ruggero, 2013). To better understand these processes, a more detailed descrip-
tion of this complex and its activities is required. 
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mTOR PATHWAY IN THE REGULATION OF CELL GROWTH AND DIVISION 
 
mTOR,  a serine/threonine protein kinase, is one of the major regulators of 
cell growth and division in eukaryotic cells, from yeasts to humans. It was initially 
identified as a target of a drug rapamycin, which has immunosuppressant and 
anti-proliferative activities (Heitman et al., 1991). In mammalian cells, mTOR is a 
component of two large protein complexes: mTORC-1 and mTORC-2. The func-
tion and regulation of mTORC-1 is far better understood as compared to 
mTORC-2. Remarkably, mTORC-1 can sense the availability of oxygen, growth 
factors, and amino acids, as well as a plethora of stress stimuli. Essentially, 
mTORC-1 regulates cell homeostasis through its control of global protein and li-
pid synthesis, cell metabolism, and inhibition of autophagy (Figure 2). 
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Figure 2. mTOR signaling pathway. mTOR is a component of both mTORC-1 
and mTORC-2 complex. Growth factors and nutrients availability as well as 
stress and oxygen levels regulate the activity of mTORC-1. In response to these 
stimuli, mTORC-1 affects lipids and protein synthesis rates as well as autophagy. 
The above schematic has been modified from Laplante and Sabatini, 2012. For 
details, see text.  
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Upstream regulators of mTORC-1 
 
mTORC-1 is a complex of multiple proteins with separate functions. 
mTOR is a serine/threonine kinase. It specifically associates with regulatory-
associated protein of mTOR (RAPTOR), which determines substrate specificity 
of the mTORC-1 complex (Asnaghi, et al., 2014). RAPTOR recognizes its sub-
strates by binding to TOS motifs (Schalm et al., 2003). Another central mTORC-1 
component is the structural protein mammalian lethal with SEC13 protein 8 
(mLST8). Besides these core components, other proteins can associate to the 
mTORC-1 complex. Proline-rich AKT-substrate of 40 kDal (PRAS40) is thought 
to be an mTORC-1 inhibitory protein whose properties are lost or greatly dimin-
ished upon AKT phosphorylation (Laplante and Sabatini, 2009). Another loosely 
associated protein is ras homologue enriched in brain (Rheb). This protein is 
necessary for mTORC-1 activity when it is bound to GTP. The mTORC-1 com-
plex is considered to intrinsically sense amino acids availability (especially leu-
cine and asparagine; Avruch et al., 2006). However, this sensing capability is 
completely lost in the absence of Rheb, along with any kinase activity. The major 
cellular inhibitor of mTORC-1 is the tuberous sclerosis complex (TSC), a large 
heterodimer of TSC-1 (hamartin) and TSC-2 (tuberin). The main functions of TSC 
are to promote hydrolysis of GTP bound to Rheb and convert the complex into 
Rheb-GDP (Laplante and Sabatini, 2012). 
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In response to growth factor stimulation, such as insulin, the PI3K/AKT 
and Ras/ERK1/2 pathways inactivate TSC1/2 and activate mTOR kinase (Man-
ning et al., 2002; Ma et al., 2005).  
The tyrosine kinase growth factor receptors activate Phosphoinositide 3-
kinase (PI3K), which phosphorylate phosphoinositides and generate phosphati-
dylinositol (3,4,5)-trisphosphate (PIP3). PIP3 recruits AKT to membrane com-
partments (including the plasma membrane) where it is first phosphorylated by 
phosphoinositide dependent kinase 1 (PDPK1) at T308 (Peltier et al., 2007). 
mTORC-2 further phosphorylates AKT at S473 (Sarbassov et al., 2005). In gen-
eral, AKT phosphorylated at T308 is mostly responsible for AKT functions on 
mTORC-1, while fully phosphorylated AKT (at both T308 and S473) is involved in 
the regulation of CREB, FOXO transcription factors, and hyperactivation of pro-
survival, anti-apoptotic proteins (Peltier et al., 2007; Rafalski and Brunet, 2011, 
Laplante and Sabatini, 2012). AKT is a central regulator of mTORC-1. It inhibits 
TSC2 by phosphorylating it at multiple sites, thus activating mTORC-1 (Zhang et 
al., 2003). It also phosphorylates and inactivates the proline-rich AKT substrate 
40 (PRAS40) at T246. PRAS40 is an additional mTORC-1 inhibitor (Sancak et al., 
2007).  
ERK1/2 have also be shown to phosphorylate TSC2 but at different sites 
than AKT. This phosphorylation inhibits the Rheb-GAP activity of the TSC1/TSC2 
complex and is thought to promote TSC1-TSC2 dissociation (Ma et al., 2005). 
Thus, the ERK1/2 pathway activates mTORC-1.  
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While amino acid levels can enhance mTORC-1 activity via Rag GTPases 
(Kim et al., 2008) chronic stress leads to repression of mTORC-1 activity.  
Low energy status or low oxygen content (hypoxia) causes activation of 
adenosine monophosphate-activated protein kinase (AMPK) that activates TSC2, 
inhibiting mTORC-1 (Gwinn et al., 2005). AMPK not only exerts its function via 
the regulation of TSC, but also through the phosphorylation of RAPTOR, com-
promising mTORC-1’s function (Gwinn et al., 2008). Hypoxia also regulates ac-
tivity of mTORC-1 via upregulation of REDD1, which then activates TSC1/2 
(DeYoung at al., 2008). DNA damage increases the expression of TSC2 and, 
consequently, inhibits mTORC-1 (Feng et al., 2005). 
 
Downstream targets of mTORC-1 
 
mTORC-1 regulates cell growth via multiple pathways. It positively regu-
lates protein synthesis via phosphorylation of 4E-BP1 (mainly at threonine 37/46, 
T37/46). 4E-BP1 is a central repressor of protein synthesis where both the PI3K/ 
AKT and the Ras/MEK signaling pathways converge to promote tumorigenicity 
(She et al., 2010). 4E-BP1 binds the eukaryotic initiation factor eIF4E and pre-
vents the formation of the eukaryotic initiation of translation complex (collectively 
known as eIF4F; Parsyan et al., 2010). Phosphorylation of 4E-BP1 at T37/46, 
followed by the phosphorylation at threonine 70 (T70) and serine 65 (S65), al-
lows eIF4E binding to eIF4G initiating protein synthesis (Sonenberg and Hinne-
busch, 2009; see below).  
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mTORC1 also phosphorylates S6K (at threonine 389), a serine/threonine 
protein kinase that regulates protein synthesis, insulin sensitivity, and cell cycle 
(Ma and Blenis, 2009; Shin et al., 2011). S6K targets many components im-
portant for protein synthesis regulation. These include eEF2K, TIF1A and eIF4B 
(Sonenberg and Hinnebusch, 2009). 
Regulation of lipid synthesis by mTORC-1 is mediated by lipin 1 and sterol 
regulatory element-binding protein 1/2 (SREB1/2) which transcriptionally acti-
vates genes related to fatty acid and cholesterol synthesis (Porstmann et al., 
2008; Peterson et al., 2011).  
mTORC-1 also contributes to cell growth by inhibition of autophagy. It 
phosphorylates and suppresses a protein complex responsible for this degrada-
tion pathway (ULK1/Atg13/FIP200) (Jung, 2009). Finally, mTORC-1 can also in-
hibit lysosomes biogenesis (Lee et al., 2009; Settembre et al., 2011). 
 
mTORC-1 and cell cycle progression 
 
mTORC-1 coordinates cell growth and cell division during G1 to S transi-
tion. This is not surprising as anabolic processes are also activated during this 
period. Every cell has to clear critical checkpoints before committing to prolifera-
tion and for progression through the cell cycle. Early in the G1 phase, the cell 
clears a growth-factor dependent restriction point (R). Mammalian cells pass this 
restriction point 3 to 4 hours post-G1 entry (Zetterberg and Larsson, 1985). How-
ever, there is another checkpoint in G1 phase. It is the late-G1 metabolic check-
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point, which is reminiscent of the G1 checkpoint known in yeast as START. It is a 
nutrient-dependent “cell growth” checkpoint that heavily relies on mTORC-1 func-
tions (Fingar and Blenis, 2004; Foster et al., 2010). The existence of this check-
point was suggested more than 30 years ago. In one experiment, mouse fibro-
blasts were starved of amino acids or treated with mTORC-1 inhibitor rapamycin. 
These cells arrested at the G1 phase just like upon growth factor withdrawal. 
However, replenishing cells arrested at START with amino acids caused these 
cells to re-enter the cell cycle much faster than cells forced into quiescence after 
growth factors deprivation (Yen and Pardee, 1978). In another experiment, Stiles 
et al. noticed that even if the exposure of cells to platelet-derived growth factor 
(PDGF) is sufficient for cell cycle commitment, progression through the G1 phase 
required continuous insulin-like growth factor-1 (IGF1) treatment (Stiles et al., 
1979). IGF1 activates mTORC-1 via PI3K/mTOR signaling pathway. These and 
other experimental data strongly support the existence of the mTORC-1 depend-
ent metabolic checkpoint. 
As mTORC-1 signaling regulates essential cellular processes, its deregu-
lation is associated with different human disorders including cancer, obesity, dia-
betes, cardiovascular disease, and aging (Laplante and Sabatini, 2012). Muta-
tions within the mTORC-1 signaling pathway that activate mTORC-1 can force 
cells to bypass the metabolic checkpoint; these hereditary syndromes are char-
acterized by tumor-like growths in different organs. This is best represented in 
Cowden syndrome and tuberous sclerosis complex (Brook-Carter et al., 1994; 
Liaw et al., 1997), disorders characterized by the uncontrolled growth of 
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hamartomas in multiple organs. On the other hand, downregulation of compo-
nents of the PI3K/mTOR pathway (for example Igf-1and Igf-2 null mutations or 
AKT2 and AKT3 mutations) results in organ hypoplasia and a growth deficiency 
in mice (Liu et al., 1993; Dummler et al., 2006). 
One of the best-characterized pathways regulated by mTORC-1 is protein 
synthesis. Its deregulation was implicated in different human pathological condi-
tions including cancer (Le Quesne et al., 2010). A large plethora of empirical evi-
dence support the notion that deregulated protein synthesis can lead to malig-
nant transformation (Ruggero and Pandolfi, 2003). Aberrant expression of initia-
tion factors (especially eIF4E, which is upregulated in the vast majority of malig-
nancies;	  De Benedetti and Graff, 2004), mutations of ribosomal proteins, and 
translation ancillary factors lead to so-called ribosomopaties that seem to sustain 
the malignant phenotype (Ruggero, 2013). Protein translation is one of the most 
complex mechanisms in eukaryotic cells. Most of its regulation takes place at the 
stage of the pre-initiation complex formation on the mRNA cap. This process is 
universally considered the rate-limiting step in protein translation.  
 
INITIATION OF PROTEIN SYNTHESIS AND ITS REGULATION 
 
Protein synthesis is an essential biological process that allows the conver-
sion of information encoded by the genetic code into protein molecules with a va-
riety of cellular activities. It is one of the most complex and highly regulated pro-
cesses consisting of three major stages: initiation, elongation, and termination 
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(Figure 3). Initiation involves the interactions between translation initiation pro-
teins, initiator tRNA (transfer RNA), and small ribosomal subunit 40S on mRNA 
(messenger RNA). After start codon recognition, the large ribosomal subunit 60S 
joins to form a translation elongation competent complex 80S. Translation termi-
nates at a stop codon and results in dissociation of the newly synthesized poly-
peptide from tRNA and ribosomal subunits from mRNA.  
Translation initiation is the protein synthesis step where most regulation 
occurs (Sonenberg and Hinnebusch, 2009; Spriggs et al., 2010). Regulation dur-
ing elongation is mostly restricted to phosphorylation of eEF2, resulting in protein 
synthesis arrest after lethal cellular injuries (Hizli et al., 2013). Notably, any de-
fects during translation elongation cause the ribosomes to stall on substrate 
mRNAs (Buchan and Stansfield, 2007; Lykke-Andersen and Bennett, 2014). This 
ribosomal pausing during elongation was, for example, associated with the de-
fects in the protein folding mechanism (Liu et al., 2013). The cellular responses 
to translational pausing often result in frame shifting mutation and aberrant 
mRNA production, or ribosomes drop off and mRNA decay (Buchan and Stans-
field, 2007). The endonucleolytic cleavage of mRNAs near the site where ribo-
somes stall is referred to as “no-go decay” (Doma  and Parker, 2005). 
Some translational regulation takes place during termination. However, 
since termination is mechanistically linked to initiation, it appears that modulation 
of termination mostly affects protein synthesis initiation (see below). 
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Figure 3. Eukaryotic translation initiation. Simplified mechanism of protein 
synthesis focusing on the cap-dependent translation initiation with indicated ac-
tion of inhibitors used in this project.   
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The mechanism of eukaryotic translation initiation 
 
Translation initiation of the vast majority of eukaryotic mRNAs is cap-
dependent, although cap-independent mechanisms of initiation also exist (re-
viewed below). The m7GpppN (where N stands for any nucleotide) structure 
called a cap is located at the 5’ end of cellular mRNAs. Translation initiation in-
volves recruitment of a 43S pre-initiation complex to the cap, mediated by eukar-
yotic translation initiation factors (eIFs). The pre-initiation complex includes the 
initiating methionyl-tRNA (Met-tRNAMet), GTP-bound factor eIF2, and small ribo-
somal subunit 40S. The formation of the pre-initiation complex is mediated by 
factors: eIF3, eIF1, eIF1A, and eIF5. eIF3 is a multisubunit factor that contains 
between 11 and 13 subunits (eIF3a -eIF3m) (Hinnebusch, 2006). eIF3 facilitates 
the binding of eIF2- Met-tRNAMet and the 40S ribosomal subunit. It also mediates 
the binding between the 43S pre-initiation complex and mRNA via its interaction 
with the scaffold protein eIF4G, which is present within the eIF4F complex. eIF3 
also plays a role in scanning for an initiation codon and in post-translational dis-
sociation of ribosomal subunits. eIF1 and eIF1A also regulate the scanning 
mechanism.  
Initiation codon recognition results in the codon-anticodon base pairing 
and formation of the 48S complex. eIF5 is a GTPase-activating protein (GAP) 
that promotes GTP hydrolysis on eIF2 after recognition of an initiation codon. 
Conversely, the GDP to GTP transition on eIF2 is mediated by the GTP ex-
change factor (GEF) eIF2B (Jackson et al., 2010). The affinity of GDP-bound 
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eIF2 to Met-tRNAMet is drastically reduced and it is partially lost from the 48S 
complex. Joining of the large ribosomal subunit 60S with GTP-bound eIF5B pro-
motes complete displacement of eIF2 and release of the other factors (eIF1, eIF3, 
eIF4B or H, eIF4F and eIF5). Hydrolysis of eIF5B-bound GTP promotes the dis-
sociation of eIF1A and GDP-bound to eIF5B itself, and the formation of transla-
tion elongation competent 80S ribosome (Jackson et al., 2010).  
 
eIF4F complex 
 
As mentioned above, the eIF4F complex mediates binding between the 
pre-initiation complex and mRNA. It consists of a cap-binding protein eIF4E, 
ATP-dependent RNA helicase eIF4A, and a large scaffolding protein eIF4G. 
Binding of eIF4E and eIF4A to eIF4G is anti-cooperative (LeFebvre, 2006). 
eIF4G additionally binds: eIF3 (attached to a ribosomal subunit), poly(A) binding 
protein PABP (which binds the poly(A) tail of mRNA) and Mnk1/2 or MAPK-
interacting serine/threonine kinase (which phosphorylates eIF4E). eIF4E binding 
to the cap is secured between two tryptophan residues in a concave surface of 
eIF4E and is further stabilized by interaction with the proximal nucleotide of the 
cap. Binding of eIF4G strengthens the binding of eIF4E to mRNA (von der Haar 
et al., 2004). Importantly, the simultaneous interaction between eIF4G, eIF4E, 
and PABP allows for the circularization of mRNA, making a “closed loop” (Pesto-
va et al., 2007). It has been suggested that it increases the efficiency of transla-
tion initiation by stabilizing the initiation complex for efficient and fast recycling of 
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the components of translation initiation machinery after protein synthesis termi-
nates (Gallie, 1991).  
Eukaryotic mRNAs possess secondary structures with varying levels of 
complexity. Unwinding of these structures is mediated by the DEAD-box RNA 
helicase eIF4A, which requires ATP and is aided by the ancillary factors eIF4B, 
eIF4H, and even eIF4G. The interaction of eIF4A with eIF4G, and eIF4B and/or 
eIF4H, allows eIF4A to undergo conformational changes, increasing its ligand 
binding affinity, processivity, and rate of ATP hydrolysis. eIF4A is a founding 
member of the DEAD-box helicases family whose name comes from the pres-
ence of the ATP binding motif containing the D-E-A-D (asp-glu-ala-asp) se-
quence. Interestingly, eIF4A is the most abundant translation initiation factor and 
its expression in yeast is five times higher than ribosomes (von der Haar and 
McCarthy, 2002). There are three mammalian eIF4A proteins: eIF4AI (DDX2a), 
eIF4AII (DDX2b), and eIF4AIII (DDX48). The eIF4AI and eIF4AII both play a role 
in translation initiation. The eIF4AIII, on the other hand, is involved in pre-mRNA 
splicing and mRNA localization (Andreou and Klostermeier, 2012). eIF4AI is by 
far the most studied protein of the family. Its helicase core consists of well-
characterized motifs that bind both ATP and RNA. This helicase core changes 
between an open and closed conformation allowing for the unwinding of RNA.  
The activity of eIF4A is regulated by eIF4G, eIF4B, and eIF4H. There are 
two binding sites for eIF4A within the eIF4G protein (HEAT1 and HEAT2 do-
mains). The N’ terminus HEAT domain aligns the DEAD-box helicase motif of 
eIF4A and promotes its helicase activity while the C’ terminal HEAT2 plays a 
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regulatory function (Marintchev et al., 2009). The eIF4B, and to a lower extent its 
homolog eIF4H, increases the helicase activity of eIF4A. Additionally, eIF4B co-
operates with eIF4G in increasing the efficiency with which ATP hydrolysis by 
eIF4A is coupled to RNA unwinding (Ozes et al., 2011). It is also suggested that 
eIF4B and eIF4H may increase the processivity of eIF4A by preventing the 
mRNA from re-annealing (Marintchev et al., 2009). 
 
Internal ribosome entry site- mediated mechanisms of translation initiation  
 
The alternative mechanism of translation initiation in eukaryotes involves 
the recruitment of ribosomes to internal ribosome entry sites (IRES) and is inde-
pendent of recognition of the mRNA 5' cap. This alternative mode of translation 
initiation receives increasing attention because of its importance in pathological 
stress conditions when cap-dependent translation is compromised (Komar and 
Hatzoglou, 2011). IRES are special RNA sequences located upstream of the ini-
tiation codon. They were initially found in viral genomes and, soon after, in some 
mRNAs of the eukaryotic host cell. Human cells use this mode of translation initi-
ation under conditions when cap-dependent translation is inhibited like during mi-
tosis and cell differentiation. It is also used to translate mRNAs with highly struc-
tured 5’ UTR, not compatible with the canonical scanning mode. As expected this 
initiation mechanism is also used in stress conditions including endoplasmic re-
ticulum (ER) stress, hypoxia, and reduced nutrient availability (Komar and 
Hatzoglou, 2011). It does not require many traditional translation initiation factors 
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like eIF4E or eIF4G. However, eIF4A is required for the initiation of both cap- and 
IRES-dependent translation (Mokrejs et al., 2010). The IRES-transacting factors 
(ITAFs) are also important in this translation initiation process (Komar and 
Hatzoglou, 2011). Even though IRES-dependent protein synthesis is considered 
an alternative way to translate eukaryotic mRNA, it seems that it may be more 
common than originally thought. Still, more studies are required to determine the 
full scope of the cellular IRES-dependent translation. 
 
Regulation of eukaryotic translation initiation 
 
Initiation of protein synthesis is regulated at different levels. Firstly, the 
unwinding of the secondary structure of mRNA increases the accessibility of the 
cap for translation factors and allows efficient mRNA translation. As outlined 
above, it is an ATP dependent mechanism and eIF4A helicase along with other 
proteins are catalyzing this process. Secondly, the cap is recognized by eIF4E 
only when eIF4E is freed from its repressing binding proteins (4E-BPs or eIF4E 
binding proteins). This dissociation between eIF4E and 4E-BP1 is triggered by 
full phosphorylation of 4E-BP at four residues T37/46, T70, and S65. These sites 
are phosphorylated by mTORC-1 and other kinases, including ERKs and CDK1 
(Herbert et al., 2002; Villalonga et al., 2009). Finally, many different signaling 
pathways modify and regulate the activity and accessibility of translation initiation 
factors. For example, Mnk 1/2 kinase (recruited by eIF4G) phosphorylates eIF4E. 
This phosphorylation event seems to be dispensable in normal cells, but plays a 
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role in carcinogenesis (Proud, 2014). On the other hand, the phosphorylation of 
eIF4B positively regulates eukaryotic translation in response to a wide variety of 
extracellular signals like insulin and phorbol esters. The eIF4B protein is hyper-
phosphorylated by members of the AGC protein kinase family including p70S6K 
and p90 ribosomal S6 kinase (van Gorp et al., 2009). 
New levels of translation regulation are still being discovered, enriching 
our knowledge about this complex process. In the work I am presenting here, we 
have found a novel role of Amyloid Precursor Protein or APP in the regulation of 
protein synthesis in NSCLC cells, with a detailed description of this protein re-
ported below. 
 
APP SIGNALING PATHWAY 
 
The human Amyloid beta precursor protein (APP) was first cloned in 1987 
from neuronal tissue. Researchers were looking for a precursor of a protein sub-
unit present within the cerebral amyloid plaques in Alzheimer’s disease and 
Down’s syndrome patients (Kang et al., 1987). They identified a 695 amino acid 
long APP protein (APP695). The APP gene is localized on chromosome 21. 
There are 10 different splice variants of APP that were found in mammalian and 
non-mammalian organisms (Muller and Zheng, 2012). The major isoforms are 
APP695, with expression restricted to neuronal tissue, APP770, and APP751. 
These latter isoforms are present in non-neuronal tissues of different origin (im-
mune system, muscle, lung, kidney etc.). After being translated, APP undergoes 
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posttranslational modifications that include phosphorylation, N- or O-
glycosylation, and sulfation. 
 
Proteolytic cleavage of APP 
 
APP is a type I transmembrane glycoprotein that undergoes sequential 
cleavage events (Haass et al., 2012). APP cleavage normally proceeds via the 
non-amyloidogenic pathway without amyloid deposits. In pathological conditions 
and throughout aging, APP is cleaved following the amyloidogenic pathway, 
which results in amyloid plaque formation (both pathways are reported in Figure 
4). The prevalence of the cleavage pathway depends on many variables such as 
mutational status of APP or its cleavage enzymes, and age. First, cleavage oc-
curs within the extracellular domain and is catalyzed by either α-secretase (in 
non-amyloidogenic pathway) or β-secretase (in amyloidogenic pathway). It pro-
duces the large soluble fragments APPsα and APPsβ respectively leaving behind 
membrane bound C terminal fragments (APP-CTFα and APP-CTFβ). These car-
boxyl-terminal fragments are further processed by a large γ-secretase complex 
and produce APP intracellular domain (AICD) and either a 3-kDa peptide (from 
APP-CTFα) or Aβ (from APP-CTFβ). The 3-kDa peptide is also deposited in the 
cerebral tissue of the Alzheimer’s disease and Down’s syndrome patients, just 
like Aβ (Lalowski et al., 1996; Tekirian et al., 1998). The main aspartyl protease 
responsible for the β cleavage is called BACE1 (β-site APP cleaving enzyme) 
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(Luo et al., 2001). Many enzymes from the ADAM (a disintegrin and metallopro-
tease domain) family were suggested to cleave APP and produce APP-CTFα, 
but it seems that ADAM10 is the major α-secretase involved in APP processing 
(Kuhn et al., 2010). γ-secretase, on the other hand, is a large protein complex. 
The major components of the γ-secretase complex include presenilin, nicastrin, 
APH-1 (anterior pharynx-defective 1), and PEN-2 (presenilin enhancer 2). Prese-
nilin is responsible for the enzymatic activity of γ-secretase. A “Regulated in-
tramembrane proteolysis” model explains how exactly γ-secretase cleaves APP 
(Takami et al., 2009). It starts at the C terminus of the substrate and proceeds 
towards the N terminus of the transmembrane domain. It is a sequential multistep 
process and its cleavage sites within APP are named: γ, ε and ζ (Lichtenthaler et 
al., 2011). 
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Figure 4. Proteolytic cleavage of APP. APP can be processed via two path-
ways. First, cleavage is mediated by either α- or β-secretase (from the ADAM 
and BACE family) and results in the production of soluble fragment α (sAPPα) or 
β (sAPPβ) respectively. In both pathways, the carboxyl-terminal fragments (CTF) 
are cleaved by a large complex γ-secretase. This cleavage produces APP intra-
cellular domain (AICD) and either short peptide p3 or Aβ.  
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Many different factors can regulate APP’s cleavage, one of them being 
hypoxia. It has been reported that the incidence of Alzheimer’s disease increases 
after stroke and cerebral ischemia (hypoxia induced by the insufficient blood flow 
to the brain). Furthermore, it has been demonstrated that hypoxia increases the 
cleavage of APP by the upregulation of APP cleavage enzymes. Specifically, hy-
poxia induced factor 1 (HIF-1) was shown to up-regulate both β- and γ-
secretases (Wang et al., 2006; Zhang et al., 2007). 
 
Pleiotropic functions of APP 
 
APP belongs to a gene family that, in mammals, also includes two APP-
like proteins, APLP1 and APLP2. Both, APP and APLP2 are ubiquitously ex-
pressed, while expression of APLP1 is restricted to neuronal tissue (Slunt et al., 
1994). The sequence of all proteins is homologous within the E1 and E2 extracel-
lular domains and intracellular tail (Figure 5; Müller and Zheng, 2012). Single or 
combined mice knockouts of the members of the APP family showed that they 
are all functionally different (Aydin et al., 2012). The knockout of APP in mice 
does not result in embryonic lethality, but causes some interesting phenotypic 
changes like reduction of the body mass by 15-20%, decreased brain weight, 
and impaired locomotor activity (Zheng et al., 1995). 
Literature about APP is extensive. APP seems to play a role in numerous 
neuronal and synaptic processes, but was also shown to contribute to malignant 
growth in cells of different origin (see below; Müller and Zheng, 2012). It is still 
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debated whether APP is a receptor or a ligand. Two studies implicated that Aβ 
may act as a ligand for APP but also glycoprotein F-spondin and multi-functional 
protein Netrin-1 were shown to interact with a membrane tethered APP (Lorenzo 
et al., 2000; Lu et al., 2003; Ho et al., 2004; Lourenco et al., 2009). Thus, they 
can potentially function as APP’s ligands as well. APP has also been implicated 
in the regulation of proliferation, differentiation, synaptic activity, iron transport, 
growth of neurons, and cell adhesion (Figure 5; Dawkins et al., 2014). The extra-
cellular domain of APP was implicated in cell and synaptic adhesion, shown to 
bind extracellular matrix proteins and proteoglycans, and was proposed to inter-
act with a synaptic adhesion complex neurexin (Small et al., 1999; Norstrom et 
al., 2010). Interestingly, APPsα was suggested to have neuroprotective proper-
ties in cells of different origins like fibroblasts, kerationocytes, and neurons 
(Saitoh et al., 1989; Araki et al., 1991; Young-Pearse et al., 2008). APP was 
shown to influence many different signaling pathways. For example, Aβ oligo-
mers were shown to activate AKT signaling by inhibiting its association with PDK 
(Nizzari et al., 2007). Additionally, Aβ was also shown to hyperactivate mTOR by 
mediating the phosphorylation of the mTOR inhibitor, PRAS40 (Caccamo et al., 
2011). Another adaptor protein that binds the YENPTY motif within the cytoplas-
mic domain of APP is the growth factor receptor-bound protein 2 (GRB2). It binds 
phosphorylated tyrosine residue of APP via its SH2 domain. This promotes the 
phosphorylation of Erk1/2 and activation of MAPK pathway, a major regulator of 
proliferation (Nizzari et al., 2007). 
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Figure 5. Pleiotropic functions of APP. APP’s domain composition is present-
ed on the left and corresponding functions are indicated on the right. APP is a 
transmembrane protein that contains extracellular portion (Ectodomain 1 and 2), 
transmembrane and cytoplasmic domain. Greek letters symbolize the proteolytic 
cleavage sites for α- and β-secretases and three sites of γ-secretase cleavage.  
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AICD 
 
The cytoplasmic domain of APP has also been extensively studied and 
implicated in important intracellular signaling pathways like signal transduction, 
gene regulation, and trafficking. The approximately 6-kDa sized C terminus of 
APP or AICD contains a YENPTY motif that is conserved in all APP family mem-
bers. Normally, AICD is very unstable but binding of an adaptor protein Fe65 
(through its phosphotyrosine binding domain) stabilizes AICD (Kimberly et al., 
2001). AICD along with Fe65 can translocate to the nucleus and interact with a 
histone acetyltransferase Tip60 or Tat-interactive protein (Gao and Pimplikar, 
2001). This results in transcriptional regulation of various genes. Many different 
transcriptional targets of AICD have been identified, for example APP, BACE-1, 
aquaporin-1, and NEP (Figure 6). Besides Fe65, AICD can bind about 20 inde-
pendent cellular partners and has been implicated in a variety of cellular pro-
cesses, including cytoskeleton organization (Beckett, 2012). Transcriptional ac-
tivity of AICD was also confirmed by the finding that AICD interacts with a com-
ponent of the eukaryotic transcriptional mediator complex MED12 (Turner et al., 
2011; XU at al., 2011).  
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Figure 6. AICD and its function. Some of the binding partners of AICD include 
Fe65, Tip60 and MED12. They localize to the nucleus and regulate transcription 
of genes involved in different pathways. Some of them are indicated in the table.  
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APP in cancer research 
 
One of the first studies on the role of APP in human tumors was per-
formed in colon cancer. It was shown that soluble APP fragments promote prolif-
eration of colon carcinoma cells. It has been suggested that it may be mediated 
via APP’s regulation of ERKs (Meng et al., 2001). Hansel et al. also showed that 
increased expression and cleavage of APP in pancreatic cancer promotes cell 
proliferation (Hansel et al., 2003). Additionally, APP was found to be upregulated 
in thyroid and parathyroid tumors and to regulate cell differentiation (Haven et al., 
2004; Krause et al., 2008). APP is also involved in the regulation of the andro-
gen-dependent growth of prostate cancer. (Takayama et al., 2009). Recently, 
studies confirmed that APP responds to androgen signaling and promotes prolif-
eration of breast cancer cells (Takagi et al., 2013). Overall, APP has been found 
to be upregulated in human tumors of different origin and to regulate proliferation 
and differentiation of cancer cells. Whether this is mainly due to the regulation of 
ERK signaling or if other signaling pathways are also involved remain to be es-
tablished. 
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DISSERTATION OUTLINE 
 
Studies in an orthotopic NSCLC mice model revealed that a treatment with 
an inhibitor of γ-secretase (GSI) induced cell death and phosphorylation of 4E-
BP1 (p4E-BP1) at T37/46 in hypoxic NSCLC cells. 4E-BP1, a cell growth marker, 
is one of the downstream targets of the mTORC-1 complex. The initial hypoth-
esis of this dissertation was that γ-secretase treatment could reactivate mTORC-
1 activity in a quiescent hypoxic tumor environment. To pursue our hypothesis, 
we have first investigated if GSI has the same effect on NSCLC cell lines. All ex-
periments were performed in hypoxic environment: 0.5% O2, 5.0% CO2, and 94.5% 
N2. These conditions do not restrict the growth of cancer cells and in these condi-
tions the O2 consumption rate and ATP synthesis of mitochondria are not com-
promised (Höckel and Vaupel, 2001). We showed that γ-secretase treatment in-
creases p4E-BP1 at T37/46 also in vitro. However, instead of focusing on γ-
secretase, which regulates many cellular processes, we decided to look for a pu-
tative target of this enzyme that could mediate the observed phenotype. We fur-
ther showed that depletion of APP, a well-established γ-secretase cleavage tar-
get (McCarthy et al., 2009), mirrors the enhanced phosphorylation at T37/46. 
Overexpression of APP intracellular domain (AICD), a transcription regulator, had 
an opposite effect. To find transcriptional target(s) of APP that could mediate the 
change on p4E-BP1, we have used genome-wide, discovery-driven approaches, 
such as Illumina gene expression and antibody arrays. This allowed us to identify 
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a novel target of APP, the pseudophosphatase STYX. Depletion of STYX en-
hanced p4E-BP1 at T37/476. Further studies showed that APP causes extensive 
rearrangement of 4E-BP1 phosphorylation. We also showed that APP affects 
translation initiation complex formation. Considering the changes on p4E-BP1 
and translation initiation complex, we hypothesized that APP may be involved 
in the regulation of protein synthesis rate. Fluorescence-based experiments 
with methionine surrogate confirmed our hypothesis. We also investigated if APP 
can regulate both mechanisms of translation initiation  (cap- and IRES-
dependent) using a bicistronic vector from which two luciferase genes are trans-
lated via two different modes. Since mTORC-1 is a major regulator of protein 
synthesis, our further focus was on the potential involvement of the mTORC-1 
complex in the observed phenotype. This allowed us to discard our initial hy-
pothesis. The observed change on protein synthesis upon APP depletion 
seemed to be independent of mTORC-1 activity.  
Since, cell growth and cell cycle are interdependent processes, we fur-
ther hypothesized that APP depletion may affect cell cycle progression. 
Cell cycle analysis using different techniques showed that APP promotes G0 to 
G1 progression. We identified cyclin C as a novel APP’s target that is involved in 
the regulation of G0 to G1 cell cycle transitions. The dissociation between cell 
growth and cell cycle progression, mediated by APP depletion, resulted in in-
creased cell size and cell death of hypoxic NSCLC cells. 
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In summary, we showed that APP is necessary for cell growth and cell cy-
cle progression in hypoxic NSCLC cells. We also suggest that APP may be a val-
id target in hypoxic NSCLC treatment. 
 
 
 
 
` 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
Cell culture 
 
NSCLC cell lines (H1299, A549, H1437, and H1650) and human lung 
fibroblasts (WI-38) were purchased from ATCC (Manassas, VA). NSCLC cells 
were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). 
The mesothelioma cell line (Me16) was a gift from Dr. Harvey I. Pass (New York 
University) and an immortal human keratinocyte cell culture (HaCaT) was a gift 
from Dr. Mitchel Denning (Loyola University Chicago). Both Me16 and WI-38 
were grown in DMEM supplemented with 10% FBS. Media and FBS were 
purchased from Life Technologies (Grand Island, NY) except for EMEM, which 
was purchased from ATCC.  
All cell lines were fingerprinted using the GenePrint fluorescent STR 
system (Promega, Madison, WI). We also screened cell cultures for 
mycoplasma contamination using the MycoSensor qPCR assay kit (Stratagene, 
La Jolla, CA). Cells were cultured under hypoxic conditions (0.5% O2, 5.0% 
CO2, 94.5% N2) in a Coy CleanSpot glove-box incubator (Coy Laboratory 
Products, Grass Lake Charter Township, MI).
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Animal work 
 
The Loyola Institutional Animal Care and User Committee at the Loyola 
University Chicago Medical Center approved all animal work. Five-week-old 
female NOD.CB17-Prkdcscid/J mice (Jackson Laboratories, Bar Harbor, ME) 
were injected via lateral tail vein with 2.5 × 106 cells in 100 µl of sterile saline 
solution. Injected cell lines included A549 and H1437, which were transduced 
with a lentivirus expressing luciferase (ViraPowerTM T-Rex Lentiviral 
expression system, Grand Island, NY). During the studies, animals were housed 
in a pathogen-free animal facility at Loyola University Medical Center. Mice were 
monitored daily until they reached one of the end points (observed: dyspnea or 
irritability). At the time of euthanasia, human cells comprised 93% ± 0.8% of the 
total lungs of the mice (Eliasz et al., 2010). Tumor burden was assessed using 
bioluminescence imaging (Xenogen Vivo-Vision IVIS 100 In Vivo Imaging 
System, Caliper Life Science, Hopkinton, MA) and, after euthanasia, by 
quantitative polymerase chain reaction (PCR) determination of human to mouse 
GAPDH ratio.  
The γ-secretase inhibitor (GSI) MRK-003 was administered by oral 
gavaging at a dose of 100 mg/kg in 0.05% methylcellulose 3 days a week. After 
euthanasia, lungs, livers, and brains were harvested and flash frozen for 
molecular analyses. 8 µm thick slides of frozen lungs were used in 
immunofluorescence experiments for the marker of hypoxia GLUT-1, for 
proliferation marker Ki67, and phosphorylation of 4E-BP1 at T37/46, a marker of 
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active protein synthesis. Fixation was performed with 3.7% paraformaldehyde in 
PBS for 15 minutes, followed by permeabilization with 50 mM NH4Cl in PBS 
containing 0.1% Triton X-100 for 15 minutes. 5% BSA in PBS (0.05% Triton X-
100) was used as a blocker and antibodies were diluted in 1% BSA in PBS 
supplemented with 0.05% Triton X-100. The fluorescently labeled secondary 
antibodies used in this work were goat anti-mouse or goat anti-rabbit Alexa 
Fluor 488 (or 568) (Life Technologies). All antibodies were used at the 
concentrations recommended by the manufacturer. 
In vivo bromodeoxyuridine (BrdU) incorporation was performed according 
to the manufacturer instruction (FITC BrdU Flow kit, BD Pharmingen, San Jose, 
CA). In situ TUNEL assay was performed using the manufacturer’s protocol 
(refer to Liang et al., 2012).  Images were acquired with an AX80 microscope 
(Olympus, Center Valley, PA, USA). 
 
Reagents 
 
The γ -secretase inhibitor MRK-003 was a generous gift from Merck & 
Co. (Whitehouse Station, NJ). 5 µM MRK-003 was used in the in vitro 
experiments unless otherwise stated in figure legends. Torin 1 (1-[4-[4-(1-
Oxopropyl)-1-piperazinyl]-3-(trifluoromethyl)phenyl]-9-(3-quinolinyl)-benzo[h]-
1,6-naphthyridin-2(1H)-one) (Tocris Bioscience, Bristol, UK) was used at a final 
concentration of 250 nM. Roscovitine (Cell Signaling, Danvers, MA) was used at 
a final concentration of 20 µM. UO126 (Selleck Chemicals, Huston, TX) was 
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used at a final concentration of 10 µM. Silvestrol (Medchemexpress LLC, 
Princeton, NJ) was used at a final concentration of 40 nM and 100 nM. 
Homoharringtonine (Tocris Bioscience) was used at a final concentration of 100 
nM. All of the above chemicals were dissolved in DMSO (Sigma-Aldrich, Atlanta, 
GA). Insulin (Sigma-Aldrich) was diluted in sterile PBS and used at the specified 
concentrations. MG132 (C2211; Sigma-Aldrich) was dissolved in DMSO and 
used at a final concentration of 30 µM. Propidium Iodide (PI; 81845; Sigma-
Aldrich) was dissolved at 1 mg/ml in distilled water and used at the specified 
concentrations. Acridine Orange (AO; Life Technologies Corp.; Carlsbad, CA) 
was dissolved in distilled water at a 10 mg/ml concentration and used as 
specified below. 
 
Plasmids 
 
pcDNA3-RLUC-POLIRES-FLUC expressing both Renilla and firefly 
luciferase was a gift from Nahum Sonenberg (McGill University, Montreal). The 
schematic of the vector is presented in Figure 7. The Renilla luciferase mRNA is 
translated in a cap-dependent fashion, while the firefly luciferase mRNA is 
translated through the poliovirus internal ribosomal entry sequence (IRES).  
Bioluminescence was normalized for the expression of plasmid DNA 
using luciferase specific primers and Q-PCR. pCDF1-MCS1-EF1-cop GFP 
expressing 59 aa long APP C-terminal fragment (AICD) was a gift from Dr. Xiao 
Z.C. (Institute of Molecular and Cell Biology, Singapore); pCAX expressing full 
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length APP (isoform 695 aa long) was purchased from Addgene (Cambridge, 
MA). We used the empty plasmids as transfection controls. 
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Figure 7. Schematic representation of the bicistronic vector used for 
assessment of the cap- and internal ribosome entry site (IRES)- mediated 
translation. The Renilla reniformis, Poliovirus IRES and firefly luciferase (Luc) 
genes are cloned in the pcDNA3 vector backbone. Renilla and firefly luciferase 
gene expression is driven by the CMV promoter upstream of the Renilla 
luciferase gene (Addgene plasmid # 45642; Poulin et al., 1998).  
 
Renilla Luc Polio IRES Firefly Luc 
pcDNA3-RLUC-POLIRES-FLUC 
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Transfection experiments 
 
Most of the transfection experiments were performed using 
electroporation. Briefly, after trypsinization, cells were washed with 10 ml of 
Opti-MEM (serum free) to remove residual serum and improve transfection 
efficiency. After counting, 3 million cells in 600 µl of Opti-MEM were transferred 
to 0.4 cm-wide electroporation cuvettes (Bio-Rad, Los Angeles, CA). For 
transfection experiments, 6 µL of 200 nM of siRNA or 4 µg of plasmid was used 
per cuvette. Cells were transfected by GenePulser Xcell (Bio-Rad) under the 
following settings: 300 V for 25 msec with only 1 total pulse. Following 
transfection, cells were immediately resuspended in 7 ml of media 
supplemented with 10% FBS and 1 million cells were plated per 10 cm diameter 
tissue cultures dishes. Cells were allowed to recover overnight in normoxic 
conditions at 37°C and the following day all plates were transferred into the 
hypoxia glovebox. Unless otherwise stated, most experiments were performed 
48 hours after transfection, when the effects of the transfections were 
experimentally determined to be at their peak. In some experiments, transfection 
of plasmid DNA was done using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), 
according to the manufacturer’s protocol.  
For the APP depletion experiments, we tested three different siRNA 
against APP from: Santa Cruz Biotechnologies, Cat no: sc-29677 (Santa Cruz, 
CA) and two from Qiagen, siRNA9 Cat no: SI02780281 and siRNA10 Cat no: 
SI02780288 (Valencia, CA). The majority of experiments were performed with 
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SI02780288, which targets the 3’ terminus of all ten APP isoforms, and which 
yielded the most reproducible results. Landmark experiments (for example, the 
in vitro BrdU incorporation assay) were confirmed by using two shRNAs against 
APP from Sigma-Aldrich, Cat no: TRCN0000011043 and TRCN0000006707. 
We confirmed efficient APP downregulation in each experiment by Western blot 
analysis. 
 
Protein analysis 
 
For sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) and Western Blotting, cells were washed with PBS and trypsinized. Cell 
pellets were washed with ice-cold PBS twice and resuspended in RIPA lysis 
buffer on ice (0.1% SDS, 1% NP-40, 200 µM PMSF, 0.5% sodium deoxycholate, 
0.2  mM sodium vanadate, 50 mM sodium fluoride, protease inhibitor cocktail 
[Sigma-Aldrich], and phosphatase inhibitor cocktail [Sigma-Aldrich] in PBS). 
Lysates were sonicated and insoluble material was removed by 15 minutes 
centrifugation at 14,000 rpm at 4°C. Protein concentration was determined using 
Bradford assays. Specific amount of proteins (experimentally determined for the 
antibody used, ranging from 25 to 100 µg) were mixed with a Laemmli sample 
buffer (for 2X: 100 mM Tris-HCl pH 6.8, 4% SDS, 0.2% (wt/vol) bromophenol 
blue and 20% glycerol), heated at 95°C for 5 minutes, and loaded on SDS-PAGE 
gels. The molecular weight reference PageRuler Plus Prestained Protein Ladder 
from Thermo Scientific was used. After electrophoresis proteins were 
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electrotransferred onto Hybond-C Extra nitrocellulose membrane (Amersham 
Biosciences) overnight at 4°C. As a blocking agent, a non-fat, dry milk dissolved 
in TBS-T buffer (1X TBS with 0.1% Tween-20) was used. For primary antibody 
dilution, either blocking solution or 5% (wt/vol) bovine serum albumin (BSA, this 
blocking solution was used for Cell Signaling antibodies) in TBS-T were used. 
The length of the primary antibody incubations was determined according to the 
manufacturer’s recommendations. Secondary antibodies were diluted in blocking 
solution and incubated for 45 minutes at room temperature (RT). Washes 
between the incubations were done with freshly prepared TBS-T buffer. Proteins 
were visualized using chemiluminescent reagent ECL (SuperSignal West Dura 
Extended Duration Substrate, Prod# 34076, Thermo Scientific) and exposed to x-
ray films (Denville Scientific Inc.). At the end of the experiments, membranes 
were stained with Ponceau S solution (Sigma-Aldrich) to confirm equal loading in 
each lane.  
For immunoprecipitation experiments, cell lysates were incubated with an 
antibody at the recommended concentration overnight at 4°C. Protein A/G 
Magnetic Beads (Thermo Fisher Scientific Inc., Waltman, MA) were washed in 
TBS-0.1% Tween, and incubated with samples for 1h at room temperature with 
rotation. Elution was performed in 2X sample buffer followed by SDS-PAGE and 
Western Blotting.  
For immunofluorescent microscopy, 30,000 transfected cells were plated 
in 4-well glass slides (Chamber Slide, Lab-TekII, Rochester, NY). 48h after 
transfection, cells were rinsed with PBS, fixed in 3.7% paraformaldehyde 
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(Electron Microscopy Sciences, Haltfield, PA) for 15 minutes, washed three times 
with PBS, and permeabilized with 50 mM NH4Cl in PBS with 0.1% Triton-X. 
Blocking was performed in 5% BSA (Thermo Fisher Scientific Inc., Rockford, IL) 
in PBS with 0.05% Triton-X (DMSO,Sigma-Aldrich, St. Louis, MO)  and 
antibodies were diluted in 1% BSA in PBS with 0.05% Triton-X for a final 
concentration recommended by the manufacturers. Fluorochromes used were 
Alexa Fluor 488 and Alexa Fluor 568. The Golgi apparatus was visualized using 
rhodamine labeled wheat germ agglutinin (Vector Laboratories, Burlingame, CA). 
As a mounting medium, we used ProLong Gold Antifade Mountant with DAPI 
(Life Technologies Corp., Carlsbad, CA) that also stained nuclei. Images were 
acquired at room temperature using EVOS FL Cell Imaging System (Life 
Technologies Corp.). 
Cell Cycle and Cell Cycle Phospho Antibody Microarray were purchased 
from Full Moon BioSystems (Sunnyvale, CA). Experiments were performed 48 
hours after transfection of H1299 and A549 cell lines with either control siRNA or 
siRNA against APP. For cell lysis, protein extraction, labeling, conjugation, and 
detection we used the Antibody Array Assay Kit (Full Moon BioSystems) and 
followed the manufacturer’s protocol. Briefly, extracted cells were biotinylated, 
conjugated to the antibody array, and detected using Cy3-Streptavidin. The 
arrays were scanned and signal quantified by Full Moon BioSystems.  
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Cap binding assay 
 
Cells transfected with either control siRNA or siRNA against APP were 
collected by trypsynization 48 and 72 hours after transfection, washed with ice-
cold PBS, and frozen as cell pellets. At the time of the experiment, cell pellets 
were resuspended in 300 µl of cap binding buffer (20 mm Hepes, pH 7.2, 1 mm 
EDTA, 100 mm KCl, 10% (v/v) glycerol, 7 mm 2-mercaptoethanol, 50 mm β-
glycerophosphate, 50 mm NaF, 200 µM PMSF, protease inhibitor cocktail 
[Sigma-Aldrich] and phosphatase inhibitor cocktail [Sigma-Aldrich]). The cell 
suspension was subjected to three consecutive freeze-thaw cycles and cleared 
by centrifugation at 14,000 rpm at 4°C for 15 minutes (Villalonga et al., 2009). To 
capture cap-binding proteins, we used m7-GTP-Sepharose 4B beads (GE 
Healthcare, Cleveland, OH) and as a negative control, we used unmodified 
Sepharose 4B beads (Sigma-Aldrich). Lysates (corresponding to 100 µg of total 
protein as determined by Bradford assay) were incubated with 30 µL of beads in 
500 µL overnight at 4°C. The next day, beads were washed three times with cap-
binding buffer. Proteins associated with the cap were eluted using 40 µL Laemmli 
buffer, loaded on SDS PAGE, and blotted onto nitrocellulose membranes. 
Proteins were identified by Western Blotting using antibodies against the 
eukaryotic translation initiation factors specified in figures and figure legends. 
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Global protein synthesis rate 
 
We assess the rate of global protein synthesis using the Click-iT AHA 
Protein Synthesis kit (Invitrogen, Grand Island, NY) according to the 
manufacturer’s instruction. 48 or 72 hours after transfection media was changed 
to methionine-free medium (RPMI, no methionine GIBCO, Life Technologies 
Corp., Grand Island, NY) for 1 hour. Then, cells were incubated with the 
methionine analog Click-IT AHA (L-Azidohomoalanine) for 3 hours at a final 
concentration of 50 µM.  Fixation and permeabilization of cell membranes were 
performed according to the manufacturer’s instruction. The incorporation of AHA 
into the nascent proteins was detected with an alkyne-containing fluorescent dye 
(Alexa Fluor® 488 Alkyne) at a final concentration of 5 µM. The incorporation of 
AHA for the detection of nascent protein was analyzed by flow cytometry using a 
BD FACS Canto II instrument (Becton Dickinson, San Jose, CA) measuring 
20,000 events for each sample. Flow cytometry data was analyzed by FlowJo 
software. AHA incorporation was quantified using geometric mean fluorescence 
calculated by the software. 
For the experiments with Torin-1, we used the aforementioned protocol 
with the exception that fresh Torin-1 was added when media was changed. For 
silvestrol or homoharringtonine, cells were incubated with methionine-free media 
supplemented with 1% FBS overnight. The next morning, cells were treated with 
AHA along with silvestrol, homoharringtonine (at the concentrations specified 
above), or DMSO control for 20, 30, or 40 minutes. 
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Cell viability, cell cycle, and cell proliferation assays 
 
For cell viability, 106 cells transfected with siRNAs were washed twice in 
PBS and resuspended in 1 ml of PBS containing 20 µl of 1 mg/ml propidium 
iodide (Sigma-Aldrich, St. Louis, MO). Cells were then analyzed by flow 
cytometry as mentioned previously. 
For cell cycle analysis, cells were washed with 2 ml of 5% bovine calf serum 
(BCS). Fixation was performed in 70% ethanol and then cells were incubated 
with 250 µl of 10 µg/ml RNase A (Thermo Fisher Scientific Inc., Rockford, IL) at 
37°C for 15 minutes followed by 5 minutes at room temperature. 250 µl of 100 
µg/ml propidium iodide was added and samples were incubated for at least 1 
hour prior to flow cytometry analysis.  
To assess DNA synthesis, we used a bromodeoxyuridine (BrdU) 
incorporation (FITC BrdU Flow kit, BD Pharmingen, San Diego, CA)/7-
aminoactinomycin D (7-AAD, Sigma-Aldrich, St. Louis, MO) staining kit following 
the manufacturer instructions. After transfection with nucleic acids, cells were 
incubated with BrdU at a final concentration of 10 µM for 4 hours.   
The incorporation of propidium iodide or BrdU was analyzed by flow 
cytometry using a BD FACS Canto II instrument (Becton Dickinson, San Jose, 
CA).  
Flow cytometry data was analyzed by FlowJo software. For propidium 
iodide staining, the percentage of cells in different cell cycle phases was 
calculated using the Watson pragmatic model. For BrdU incorporation, a manual 
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gating of cells was used to calculate the percentage of cells in each phase of the 
cell cycle. 
 
Acridine orange staining 
 
Acridine Orange (AO, Life Technologies Corp., Grand Island, NY) was 
used to stain both DNA and RNA. After transfection of nucleic acids, cells were 
resuspended in culture medium at the density of 106/ml. 0.2 ml of cell suspension 
was used for further staining. 4 ml of permeabilizing solution (0.1% Triton X-100, 
80 mM HCl, 150 mM NaCl) was added to the cell suspension and 1.2 ml of ice-
cold, 1 mg/ml AO staining solution was added within 15 seconds. \ 
Samples were analyzed using both the BD FACS Canto II instrument 
(Becton Dickinson, San Jose, CA) and Amnis Image Stream X (EMD Millipore 
Corporation, Billerica, MA).  
Flow cytometry data was analyzed by FlowJo software. A manual gating 
of cells was used to calculate the percentage of cells in each phase of the cell 
cycle. 
 
Gene expression analysis 
 
Total RNA was extracted from cells using the RNeasy Mini kit (Qiagen, 
Valencia, CA). The RNA concentration was measured with a NanoDrop 
Spectrophotometer (Thermo Fisher Scientific Inc., Rockford, IL). 1 µg of total 
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RNA was used for cDNA synthesis, which was performed using the iScript 
Reverse Transcription Supermix RT-qPCR (Bio-Rad Laboratories, Hercules, 
CA).  
Quantitative real-time PCR was performed using SYBR Green PCR 
Master Mix (Applied Biosystems, Foster City, CA, USA) in an ABI 7300 thermal 
cycler (Applied Biosystems). Reactions containing water instead of template and 
non–reverse transcription reactions served as negative controls. Human 
ribosomal protein RPL13A, β-actin, and β-tubulin were used as internal reference 
genes. 
A549 and H1299 cells were transfected with siRNAs as described above. 
48h after transfection, total RNA was used for the Illumina Gene Expression 
Micro-array (HumanHT12, 48,000 probes, RefSeq plus EST).  Samples that were 
used included: untransfected A549 and H1299 cells and cells transfected with 
either siRNA or siRNA against APP from three independent transfection 
experiments.  Gene expression analysis was performed at the University of 
Chicago Genomics Core facility.  
Results were analyzed using Genome Studio software (iLLumina). We 
focused on genes in which expression either increased or decreased at least two 
fold in both cell lines. Results were confirmed with quantitative real-time PCR.  
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Statistical analysis 
 
We performed statistical analysis of our data using Student’s t test. Values 
were considered statistically significant at p < 0.05 in 2-tailed tests. 
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Table 3. List of siRNAs used in this dissertation work.  
Adapted from Sobol et al., 2015 
 
 
Target Company Cat. Number 
ALLStars Negative Control siRNA Qiagen 1027280 
APLP2_2 Qiagen SI00026761 
APLP2_6 Qiagen SI02780267 
APLP2_7 Qiagen SI02780274 
APLP2_12 Qiagen SI05165615 
APP_9 Qiagen SI02780281 
APP_10 Qiagen SI02780288 
APP Santa Cruz Biotechnology sc-29677 
ARL2 Qiagen SI00303408 
CCDC47 Qiagen SI04157188 
Cyclin C Santa Cruz Biotechnology sc-35132 
FAM3C Qiagen SI04166498 
FAM104B Qiagen SI04180064   
HABP4 Qiagen SI00433412 
NAGPA Qiagen SI00654374 
Nicastrin Santa Cruz Biotechnology sc-36063 
OSGIN1 Qiagen SI00665182 
Presenilin 1 Santa Cruz Biotechnology sc-36312 
TMED10 Qiagen SI04133108 
UBLCP1 Qiagen SI02758105 
Styx (siRNA2) Qiagen SI03665487 
Styx (siRNA3) Qiagen SI03665494 
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Table 4. List of antibodies used in this dissertation work. 
Adapted from Sobol et al., 2015 
 
 
Target Type Company Cat. Number 
Primary Antibodies 
4E-BP1 Rabbit polyclonal Cell Signaling 9452 
Akt (pan) Rabbit monoclonal Cell Signaling 4691 
APP (C-terminal) Rabbit polyclonal Sigma A8717 
APP (Aβ) Rabbit polyclonal Santa Cruz sc9129 
Cyclin C Rabbit polyclonal Abcam ab85927 
Cyclin E Rabbit polyclonal Santa Cruz Biotech. 198 
eIF4A Rabbit monoclonal Cell Signaling 2013 
eIF4E Rabbit polyclonal Cell Signaling 9742 
eIF4G Rabbit polyclonal Santa Cruz Biotech. 11373 
ERK 1/2 Mouse monoclonal Santa Cruz Biotech. 154 
GAPDH Mouse monoclonal Chemicon MAB374 
Glucose Transporter 1 
(GLUT1) Mouse monoclonal Abcam ab40084 
mTOR Rabbit polyclonal Bethyl A301-144A 
PRAS40 Mouse Monoclonal Life Technologies AHO1031 
p-4E-BP1 (Thr37/46 ) Rabbit monoclonal Cell Signaling 2855 
p-4E-BP1 (Ser 65) Rabbit monoclonal Cell Signaling 9456 
p-4E-BP1 (Thr 70) Rabbit polyclonal Cell Signaling 9455 
p70 S6 Kinase Rabbit polyclonal Cell Signaling 9202 
p-p70 S6 Kinase (Thr389) Rabbit polyclonal Cell Signaling 9205 
p-Akt (Ser 473) Rabbit monoclonal Cell Signaling 4058 
p-Akt (Thr 308) Rabbit monoclonal Cell Signaling 4056 
p-PRAS40 (Thr246) Rabbit polyclonal Life Technologies 44-1100G 
p-S6 (Ser240/244) Rabbit polyclonal Cell Signaling 2215 
p-Wee1 (Ser123) Rabbit polyclonal Abcam ab60034 
Raptor Rabbit polyclonal Invitrogen 42-4000 
S6 Rabbit monoclonal Cell Signaling 2217 
Wee Rabbit polyclonal Abcam ab37597 
p-ERK Mouse monoclonal Cell Signaling 05-481  
Presenilin-1 Goat polyclonal Santa Cruz sc-124s 
Nicastrin Rabbit monoclonal Abcam ab68145 
Secondary Antibodies 
Goat Anti-Mouse IgG (H+L), Peroxidase Conjugated Thermo Scientific 32430 
Goat Anti-Rabbit IgG (H+L), Peroxidase Conjugated Thermo Scientific 32460 
Rabbit Anti-Goat IgG Antibody,  Peroxidase 
Conjugated Millipore AP106P 
AlexaFluor 568  Rabbit IgG Life Technologies Z25306 
AlexaFluor 488  Rabbit IgG Life Technologies Z25302 
AlexaFluor 488  Mouse IgG Life Technologies Z25002 
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Table 5. Primers used for quantitative-PCR (Q-PCR) analysis. 
Adapted from Sobol et al., 2015 
 
Target Primer Sequence Accession # Positions 
4E-BP1 Fw 5’-TCGTGTGGAGCACTACCAAG-3’ NM_004095.3 441-460 
4E-BP1 Rev 5’-TGGAGGCACAAGGAGGTATC-3’ NM_004095.3 629-610 
β-actin Fw 5’-TCCCTGGAGAAGAGCTACGA-3’ NM_001101.3 787-806 
β-actin Rev 5’-AGCACTGTGTTGGCGTACAG-3’ NM_001101.3 980-961 
β-tubulin 5’-ACCTTCAGTGTGGTGCCTTC-3’ NM_178014.2 623-642 
β-tubulin 5’-GTGGCTGAGACAAGGTGGTT-3’ NM_178014.2 822-803 
Cyclin C Fw 5’-CCAGTATGTGCAGGACATGG-3’ NM_005190.3| 767-786 
Cyclin C Rev 5’-TCCACAGAAAGCTCAGCAAA-3’ NM_005190.3| 936-955 
Cyclin E Fw 5’-CAGATTGCAGAGCTGTTGGA-3’ NM_001238.2 1012-1031 
Cyclin E Rev 5’-TCCCCGTCTCCCTTATAACC-3’ NM_001238.2 1210-1191 
Nicastrin Fw 5’-CAAAGCACCTTCAGCATCAA-3’ NM_015331 833-852 
Nicastrin Rev 5’-GCCACATTCCAGAAAAAGGA-3’ NM_015331 999-980 
CCDC47 Fw 5’-ACCACTGTGGAGTTGGAAGG-3’ NM_020198.2 535-554 
CCDC47 Rev 5’-ACTCTCCCAGCTGTTCTGGA-3’ NM_020198.2 741-722 
SNORA12 Fw 5’-GGGCCTAACTCTGCCACATA-3’ NR_002954.1 46-65 
SNORA12 Rev 5’-ACATGTGGGAGCCATTCTCT-3’ NR_002954.1 147-128 
Presenilin Fw 5’- GGTAAAGCCTCAGCAACAGC-3’ NM_000021.3 1464-1483 
Presenilin Rev 5’- AAACAAGCCCAAAGGTGATG-3’ NM_000021.3 1617-1598 
RAPTOR Fw 5’-AAGATCCCAGAAGAGCACGA-3’ NM_001163034.1 3248-3267 
RAPTOR Rev 5’-ATGCTGTCCTTGTCGGCTAC-3’ NM_001163034.1 3468-3449 
APLP-2 Fw 5’-GCTGTCGTTCCGGTTATGTT-3’ NM_001642.2 2819-2838 
APLP-2 Rev 5’-GAGGGTCTCTCACGTGCTTC-3’ NM_001642.2 2993-2974 
RPL13A Fw 5’-CATAGGAAGCTGGGAGCAAG-3’ NM_012423.3 803-822 
RPL13A Rev 5’-ACAAGATAGGGCCCTCCAAT-3’ NM_012423.3 969-950 
mTOR Fw 5’-CCAACAGTTCACCCTCAGGT-3’ NM_004958.3 5189-5208 
mTOR Rev 5’-GCTGCCACTCTCCAAGTTTC-3’ NM_004958.3 5396-5377 
OSGIN1 Fw 5’-ACATGAAGTCGGTCCTCACC-3’ NM_182981.2 486-505 
OSGIN1 Rev 5’-GCTTCTTCTGCATCCAGTCC-3’ NM_182981.2 665-646 
E2F2 Fw 5’-CCTCTCCCCTCTACCTCCAC-3’ NM_004091.3 1376-1395 
E2F2 Rev 5’-AGGCTGTCAGTAGCCTCCAA-3’ NM_004091.3 1548-1529 
FAM104B Fw 5’-TGTTACTGAACCCGATGCAA-3’ NM_138362.3 246-265 
FAM104B Rev 5’-CAGCTGGAACCTCCTCTCAC-3’ NM_138362.3 468-449 
LOC728431 Fw 5’-CGTATGCGCAAGATAAGCAC-3’ NR_038842.1 121-140 
LOC728431 Rev 5’-CTGGCCGTACGTAGCTTCA-3’ NR_038842.1 280-262 
HS.475334 Fw 5’-CCCAGGGAGCCTACTACACA-3’ NM_015159.1 695-714 
HS.475334 Rev 5’-AGGGTACCTGCTGACATTGC-3’ NM_015159.1 881-862 
FAM 81A Fw 5’-TTGCAACAGGAACAAGAACG-3’ NM_152450.2 893-912 
FAM 81A Rev 5’-CCGTGCATCTTCTCCTCTTC-3’ NM_152450.2 1101-1082 
CCDC47 Fw 5’-ACCACTGTGGAGTTGGAAGG-3’ NM_020198.2 535-554 
CCDC47 Rev 5’-ACTCTCCCAGCTGTTCTGGA-3’ NM_020198.2 741-722 
H2BFS Fw 5’-CTCTAAGGCCATGGGAATCA-3’ NM_080593.2 228-247 
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H2BFS Rev 5’-TAGCGCTGGTGTACTTGGTG-3’ NM_080593.2 436-417 
UBLCP1 Fw 5’-TAAAATGGGGTGGACAGGAG-3’ NM_145049.3 346-365 
UBLCP1 Rev 5’-TTTTCTGCAGGTTTGCCTTT-3’ NM_145049.3 496-477 
ARL2 Fw 5’-GGCTCCTGACCATTCTGAAG-3’ NM_001667.3 100-119 
ARL2 Rev 5’-GTGCTCCAGGGTCTTGATGT-3’ NM_001667.3 266-247 
TMED10 Fw 5’-GTGGAGGCGAAAAATTACGA-3’ NM_006827.5 455-474 
TMED10 Rev 5’-AAGAAGCGTCGCAGGTAGAA-3’ NM_006827.5 702-683 
HABP4 Fw 5’-ACGCTTTTGACCAGAGAGGA-3’ NM_014282.2 765-784 
HABP4 Rev 5’-CTCAGGAACTTTGGCTGGAG-3’ NM_014282.2 985-966 
FAM3C Fw 5’-ATCTCAAAAGCTTGCCCTGA-3’ NM_014888.2 426-445 
FAM3C Rev 5’-AAATGGTGCCACATCTCCTC-3’ NM_014888.2 644-625 
HS.475334 Fw 5’-CCCAGGGAGCCTACTACACA-3’ NM_015159.1 695-714 
HS.475334 
Rev 5’-AGGGTACCTGCTGACATTGC-3’ NM_015159.1 881-862 
NAGPA Fw 5’-TGTGGCTGATTCGTAATGGA-3’ NM_016256.3 635-654 
NAGPA Rev 5’-GTCTGCATGAAAGAGCACCA-3’ NM_016256.3 798-779 
LOC10012903
4 Fw 5’-GAAGAGGTCAGGAGCCACAG-3’ NR_027406.1 2613-2632 
LOC10012903
4 Rev 5’-TCAGAGCAGTGGGAGAAGGT-3’ NR_027406.1 2744-2763 
LOC10012955
0 Fw 5’-TGGGAAATTGGGAATGTTGT-3’ NW_001838882.2 1971-1952 
LOC10012955
0 Rev 5’-AGCCCTGCTCTATGTGGCTA-3’ NW_001838882.2 1762-1781 
HIST1H2BK 5’-GCTCGTAGTTCGCCTTCAAC-3’ NM_080593.2 41-50 
HIST1H2BK 5’-TGATTCCCATGGCCTTAGAG-3’ NM_080593.2 247-228 
LOC201651 5’-TGGTGACTGGTGTGGATAGC-3’ NR_026915.1 109-128 
LOC201651 5’-TCCATGTCAAGCGTCTGAAG-3’ NR_026915.1 306-287 
LOC730432 
(Styx) Fw 5’- TGCTGGATTTGTCCATCAAC-3’ XM_006720242.1 361-380 
LOC730432 
(Styx) Rev 5’-CTTGCATGGTTCCAAAATCA-3’ XM_006720242.1 530-511 
APP ALL Fw 
Transcript 
Variants: 
1,2,3,4,5,6,7,8
,9,10 
5’-GCCAAAGAGACATGCAGTGA-3’ 
NM_000484.3 
NM_201413.2 
NM_201414.2 
NM_001136016.3 
NM_001136129.2 
NM_001136130.2 
NM_001136131.2 
NM_001204301.1 
NM_001204302.1 
NM_001204303.1 
660-679 
660-679 
660-679 
641-660 
492-511 
492-511 
547-566 
660-679 
660-679 
660-679 
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APP ALL Rev 
Transcript 
Variants: 
1,2,3,4,5,6,7,8
,9,10 
5’-CCAGACATCCGAGTCATCCT-3’ 
NM_000484.3 
NM_201413.2 
NM_201414.2 
NM_001136016.3 
NM_001136129.2 
NM_001136130.2 
NM_001136131.2 
NM_001204301.1 
NM_001204302.1 
NM_001204303.1 
827-808 
827-808 
827-808 
808-789 
659-640 
659-640 
714-695 
827-808 
827-808 
827-808 
APP ALL Rev 
Transcript 
Variants: 
1,2,3,4,5,6,7,8
,9,10 
5’-CTTGACGTTCTGCCTCTTCC-3’ 
NM_000484.3 
NM_201413.2 
NM_201414.2 
NM_001136016.3 
NM_001136129.2 
NM_001136130.2 
NM_001136131.2 
NM_001204301.1 
NM_001204302.1 
NM_001204303.1 
1458-1439 
1401-1382 
1233-1214 
1382-1363 
1065-1046 
1290-1271 
1120-1101 
1458-1439 
1401-1382 
1233-1214 
APP ALL Fw 
Transcript 
Variants: 
1,2,3,4,5,6,7,8
,9,10 
5’-TTCCCGTGAATGGAGAGTTC-3’ 
NM_000484.3 
NM_201413.2 
NM_201414.2 
NM_001136016.3 
NM_001136129.2 
NM_001136130.2 
NM_001136131.2 
NM_001204301.1 
NM_001204302.1 
NM_001204303.1 
2020-2039 
1963-1982 
1795-1814 
1944-1963 
1627-1646 
1852-1871 
1682-1701 
2020-2039 
1963-1982 
1795-1814 
APP ALL Rev 
Transcript 
Variants: 
1,2,3,4,5,6,7,8
,9,10 
5’-CTCCACCACACCATGATGAA-3’ 
NM_000484.3 
NM_201413.2 
NM_201414.2 
NM_001136016.3 
NM_001136129.2 
NM_001136130.2 
NM_001136131.2 
NM_001204301.1 
NM_001204302.1 
NM_001204303.1 
2411-239 
2354-2335 
2186-2167 
2335-2316 
2018-1999 
2243-2224 
2073-2054 
2357-2338 
2300-2281 
2132-2113 
APP Fw 
Transcript 
Variants: 
1,6,8 
5’-CCGCTGGTACTTTGATGTGA-3’ 
NM_000484.3 
NM_001136130.2 
NM_001204301.1 
1115-1134 
947-966 
1115-1134 
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APP Rev 
Transcript 
Variants: 
1,6,8 
5’-GGCAAGAGGTTCCTGGGTAG-3’ 
NM_000484.3 
NM_001136130.2 
NM_001204301.1 
1274-1255 
1106-1087 
1274-1255 
APP Fw 
Transcript 
Variants: 
1,2,4,6,8,9 
5’-CACAGAGAGAACCACCAGCA-3’ 
NM_000484.3 
NM_201413.2 
NM_001136016.3 
NM_001136130.2 
NM_001204301.1 
NM_001204302.1 
995-1014 
995-1014 
976-995 
827-846 
995-1014 
995-1014 
APP Rev 
Transcript 
Variants: 
1,2,4,6,8,9 
5’-ACATCCGCCGTAAAAGAATG-3’ 
NM_000484.3 
NM_201413.2 
NM_001136016.3 
NM_001136130.2 
NM_001204301.1 
NM_001204302.1 
1172-1153 
1172-1153 
1153-1134 
1004-985 
1172-1153 
1172-1153 
APP Fw 
Transcript 
Variant: 
4 
5’-CTTGCTGTGCGTGGTAGAAG-3’ NM_001136016.3 13-32 
APP Rev 
Transcript 
Variant: 
4 
5’-TCCATTTGAATCTGGGGAAG-3’ NM_001136016.3 201-182 
APP Fw 
Transcript 
Variant:  
5,6 
5’-GCTGGAGGTCTACCCTGAACT-
3’ 
NM_001136129.2 
NM_001136130.2 
251-271 
251-271 
APP Rev 
Transcript 
Variant:  
5,6 
5’-GCTGCTGTTGTAGGAACTCG-3’ NM_001136129.2 NM_001136130.2 
913-894 
1138-1123 
APP Fw 
Transcript 
Variant:  
7 
5’-CTCTCCCTCCCACTGTTCACG-3’ NM_001136131.2 116-136 
APP Rev 
Transcript 
Variant:  
7 
5’-CTGGTTGGTTGGCTTCTACC-3’ NM_001136131.2 361-342 
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CHAPTER THREE 
RESULTS 
 
NSCLC is a terminal illness with an urgent need for new treatment 
approaches. Hypoxic areas within lung cancer are associated with poor 
prognosis and tumor recurrence (Jackson et al., 2010). Hypoxia renders tumors 
resistant to both chemo- and radiotherapy. It is essential for tumor maintenance, 
promotes cancer invasiveness, and metastasis (Hill et al., 2009). Previous data 
from our laboratory have shown that Notch-1 signaling is required for the survival 
of hypoxic NSCLC cells. Notch-1 induces the expression of insulin-like growth 
factor 1 receptor (IGF-1R), its ligands IGF-1 and IGF-2, and inhibits phosphatase 
and tensin (PTEN) homolog expression. This leads to the activation of the pro-
survival AKT signaling pathway (Graziani et al., 2008; Eliasz et al., 2010). 
Canonical Notch-1 signaling is initiated by a number of proteolytic cleavage 
events and culminates in the release of the Notch intracellular domain (NotchIC), 
catalyzed by a large intramembranous protease complex named γ-secretase. To 
target hypoxic NSCLC cells, we inhibited Notch-1 signaling using a γ-secretase 
inhibitor (GSI) in an orthotropic model of NSCLC. GSI treatment prolonged the 
median survival of tumor bearing mice as compared to vehicle treated controls.
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It also decreased overall markers of tumor hypoxia, and reduced tumor 
metastasis to both brain and liver (Liang et al., 2012). We verified cancer cell 
death in hypoxic NSCLC tissue using a variety of techniques, including TUNEL 
assay. We used glucose transporter 1 (GLUT-1) as a marker of hypoxia. Staining 
of frozen lung sections showed cell death in hypoxic areas of tumors from GSI 
treated animals (Figure 8 A-D). Notably, DNA fragmentation, visualized with 
TUNEL assay, was detected outside of the cells. We also observed another 
characteristic of these cancer cells that we could not explain at that stage: cells 
exposed to GSI appeared to be larger as compared to controls (Figure 8; C and 
D compared to A and B). We thought, at first, that this could have been an 
experimental artifact. Further experiments suggested possible explanations of 
these occurrences (see below).
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Figure 8. GSI treatment causes cell death of hypoxic NSCLC cells. Top: 
vehicle treated mice. Bottom: GSI treated mice (100 mg/kg of MRK-003 in 0.05% 
methylcellulose 3 days a week).  
A and C: bright field images.  
B and D: immunofluorescent staining of 8 µm sections of frozen lungs 
(representative experiments are shown). 
Green: immunofluorescent staining of GLUT-1 (marker of hypoxia). 
Red: in situ TUNEL assay (DNA fragmentation, a marker of cell death).  
Adapted from Liang et al., 2012. 
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γ-SECRETASE INHIBITION MODIFIES 4E-BP1 PHOSPHORYLATION 
 
Additional analysis of lung tissues revealed that cancer cells in hypoxic 
tumor areas do not proliferate, as visualized by two independent assays: in vivo 
BrdU incorporation assay and Ki67 staining. GLUT-1 positive cells stain negative 
for the proliferative markers, BrdU and Ki67 (Figure 9A). We further assessed the 
metabolic properties of these cells by the activation of mTORC-1 complex. The 
mTORC-1 complex is a major regulator of cell growth and proliferation that 
controls anabolic processes of eukaryotic cells (Laplante and Sabatini, 2012). To 
assess mTORC-1 activation, we monitored the phosphorylation status of one of 
its major downstream targets, 4E-BP1, at threonines (T) 37/46 (T37/46). 4E-BP1 
is a repressor of protein synthesis and phosphorylation at T37/46 of 4E-BP1 is 
required for cap-dependent translation initiation (Villalonga et al., 2009). We did 
not detect phosphorylation of T37/46 in quiescent cancer cells within hypoxic 
regions of tumors from vehicle treated animals (two representative tumor tissues, 
Figure 9B). However, we observed co-localization of the hypoxia marker GLUT-1 
and T37/46 phosphorylation in tumors from GSI treated animals (two 
representative tumor tissues, Figure 9C). 
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Figure 9. γ-secretase inhibition enhances 4E-BP1 phosphorylation at 
T37/46.  
A. NSCLC cells in hypoxic tumor regions are quiescent. Co-immunofluorescence 
of the hypoxia marker GLUT-1 (red) and proliferation markers: Ki67 (top: green) 
or BrdU in vivo incorporation (bottom: green).  
B-C. Lung sections of two representative NSCLC bearing mice treated with 
vehicle (B) or GSI (C). Co-immunofluorescence of the hypoxia marker GLUT-1 
(red) and phosphorylated T37/46 4E-BP1 (green). Co-localization of GLUT-1 and 
phosphorylated T37/46b is visible only upon GSI treatment (yellow).  
Bright field images: bf, immunofluorescent staining: fl.  
D. Western blot analysis of the specified proteins and phosphoproteins in total 
cell lysate obtained from the indicated NSCLC cell lines upon treatment with 
vehicle (DMSO, c) or GSI.  
E. mRNA levels of 4E-BP1 as determined by Q-PCR in cells treated with 
DMSO(c) or GSI for 48h. Columns represent averages of three independent 
experiments, bars represent S.D. The mRNA abundance for cells treated with 
DMSO (c) was arbitrarily set to 1.  
F. Left: Western blot analysis of the specified proteins and phosphoproteins in 
total cell lysates obtained from NSCLC cell line H1299 after transfection with 
either a control siRNA (c), or siRNAs against preselinin-1 and nicastrin 
(siPres/Nic); Right: Western blot analysis of the specified proteins confirming 
downregulation efficiency. Similar results were obtained in other NSCLC cell 
lines A549 and H1437. 
Adapted from Sobol et al., 2015 [1]. 
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Our initial hypothesis was that GSI treatment could reactivate mTORC-1 in 
hypoxic NSCLC cells. Since mTORC-1 regulates cell growth, this reactivation 
could have explained the initially observed cell enlargement and death (Figure 
8). Active anabolic processes in the nutrient-deprived, hypoxic tumor 
microenvironment should rapidly exhaust energy resources leading to cell 
necrosis. In other terms, inappropriate mTORC-1 reactivation in cells, which 
should be under a metabolic checkpoint, could lead to energy exhaustion and 
cell death.  
We sought to confirm our findings in vitro. Because of its intrinsic 
variability, mimicking tissue hypoxia in vitro is probably impossible (Palmer et al., 
2010). We decided to culture our cells in complete medium, but preserving 
hypoxia inducible factors (HIF1α, 2α and 3α), because they collectively regulate 
a significant portion of the transcriptome under hypoxic conditions (Pawlus and 
Hu, 2013). To achieve this, we cultured our cells in a 0.5% O2, 5.0% CO2, and 
94.5% N2 atmosphere. Under these conditions, mitochondrial function is not 
compromised; hence, these conditions cannot be considered as “deep hypoxia” 
(Höckel and Vaupel, 2001). Higher oxygen concentrations did not consistently 
preserve HIFs expression (not shown). Similar to what was observed in vivo, 
treatment of various NSCLC cell lines with GSI enhanced 4E-BP1 
phosphorylation at T37/46 (Figure 9D). Three bands of total 4E-BP1 protein 
correspond to 4E-BP1 phosphorylated at the following residues: T37/46, T37/46 
plus threonine 70 (T70), and T37/46 plus T70 and serine 65 (S65) (Gingras et al., 
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2001). Merging of these bands, observed in A549, H1299 and H1650 cell lines, 
could suggest a loss of 4E-BP1 phosphorylation at S65 and/or T70 (Figure 9D). 
The total protein level of 4E-BP1 in H1437 cells increased upon GSI treatment, 
but mRNA levels remained the same (Figure 9D, E). We did not focus our 
attention on this phenomenon since γ-secretase cleaves more than 90 cellular 
substrates. Moreover, some GSI are able to diminish proteasome activity 
independently of γ-secretase inhibition (Han et al., 2009). Thus, to confirm that 
the observed change on 4E-BP1 phosphorylation can be attributed specifically to 
γ-secretase inhibition, and not to off-target effects of the drug, we downregulated 
two central components of the γ-secretase complex: presenilin and nicastrin. 
These proteins are essential for catalytic activity and substrate recognition of γ-
secretases (Herreman et al., 2003). Depletion of these proteins reproduced the 
increase in 4E-BP1 phosphorylation at T37/46 observed upon GSI treatment 
without affecting the expression of 4E-BP1 (Figure 9F). This supported the idea 
that the observed change at T37/46 was due to the inhibition of γ-secretase 
activity and not to off-target effects of the drug treatment. As mentioned above, 
the γ-secretase complex cleaves and activates more than 90 different cellular 
proteins with a variety of functions (Haapasalo and Kovacs, 2011). Therefore, 
instead of investigating the role of γ-secretase itself, we decided to identify a 
specific γ-secretase target that could mediate the observed change on 4E-BP1 
phosphorylation. 
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AMYLOID PRECURSOR PROTEIN (APP) IS THE γ-SECRETASE 
SUBSTRATE THAT ALTERS THE 4E-BP1 PHOSPHORYLATION STATUS 
 
Initially, the rationale of using GSI was to target Notch signaling, which is 
known to regulate the prosurvival AKT pathway (upstream activator of mTORC-
1) in hypoxic NSCLC (Eliasz et al., 2010). However, downregulation of all four 
Notch receptors in separate experiments or forced expression of each Notch 
receptor intracellular domains did not alter the phosphorylation status of 4E-BP1 
significantly (results not shown).  
Next, we focused on Amyloid Precursor Protein or APP. APP is one of the 
most well-known and extensively studied cleavage substrates of γ-secretase (De 
Strooper et al., 2012). APP is known to play some roles in cell proliferation 
through the regulation of different signal transduction pathways, including the 
mitogen-activated protein kinase cascade (Nizzari et al., 2007). We hypothesized 
that depletion of APP could potentially alter the phosphorylation status of 4E-
BP1. siRNA-mediated downregulation of APP increased 4E-BP1 phosphorylation 
at T37/46 in different NSCLC cell lines cultured under hypoxia (Figure 10A). The 
total levels of 4E-BP1 were unchanged. For each experiment shown here, we 
assessed the efficiency of APP’s downregulation at the mRNA and protein levels. 
A representative experiment is shown in Figure 10 (B, C). The siRNAs and 
shRNAs used in this study are specified in Materials and Methods. Generally, we 
performed pilot experiments using a siRNA targeting the shared 3’-end of all 10 
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APP splice variants and confirmed experiments using one or more alternative 
siRNA or shRNA. 
To confirm that APP signaling had a role in the regulation of 4E-BP1 
phosphorylation at T37/46, we overexpressed the APP C-terminal domain, or 
AICD, and obtained opposite results compared to APP depletion (Figure 10A). 
These results strengthened our hypothesis that APP could represent a putative γ-
secretase substrate that regulates 4E-BP1 phosphorylation. 
We wanted to further confirm that APP is active in our NSCLC cell lines. 
Activation of APP depends on its proteolytic processing and culminates with the 
cleavage by γ-secretase (Xu et al., 2011). An indication of active APP signaling 
is, therefore, its cleavage. To confirm that APP is cleaved in NSCLC cell lines, 
we treated them with GSI and assessed the accumulation of the total APP 
protein. The γ-secretase cleavage product, AICD, is only approximately 6-kDa in 
size and its detection is highly difficult, especially because available antibodies 
against it are inefficient. For this reason, we sought evidence of inhibited 
cleavage by monitoring the accumulation of full-length APP protein upon GSI 
administration. Treatment with GSI led to a dose-dependent increase in total 
APP levels (Figure 10D). This accumulation of full-length APP provided positive 
evidence that γ-secretase cleaves APP in NSCLC cell lines and that APP 
signaling is active in our cells. Multiple bands, observed by Western blot analysis, 
at high molecular weight, correspond to both isoforms of APP (which our 
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antibody is expected to detect) and post-translationally modified APP protein 
(e.g., the products of N- and O-glycosylation).  
Serine 65 (S65) and threonine 70 (T70) are two additional, major 
phosphorylation residues of 4E-BP1, which determine the extent of eIF4E 
inhibition. We assessed their phosphorylation status upon APP depletion. We 
reproducibly observed that phosphorylation of S65 decreased after APP 
downregulation in different NSCLC cell lines, while APP depletion had negligible 
effect on T70 phosphorylation (Figure 10E). 
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Figure 10. APP is the γ-secretase substrate that alters the 4E-BP1 
phosphorylation pattern.  
A. Western blot analysis of the specified proteins and phosphoproteins in total 
cell lysates obtained from the indicated NSCLC cell lines after transfection with 
either a control siRNA (c) or siRNA to APP (siAPP); and control plasmid (c) or a 
plasmid encoding APP intracellular domain (AICD).  
B. Q-PCR of APP mRNA levels on cells transfected with a control siRNA or with 
siAPP. Columns represent the average of four independent experiments (one in 
each cell line A549, H1299, H1437 and H1650); bars represent S.D. The mRNA 
abundance for cells transfected with control siRNA (c) was arbitrarily set to 1 at 
48 hours after transfection.  
C. Representative Western blot analysis of APP protein levels from the lysate 
obtained from H1299 cells at the specified time-points after siRNA transfection as 
described in B. Virtually identical results were obtained in all cells tested. The 
remaining band after APP depletion (not visible in all our Western blots) may be 
unspecific or correspond to the APP homolog protein APLP-2.  
D. Western blot analysis of the specified proteins and phosphoproteins in total 
cell lysates obtained from cell line H1299 after exposure to the indicated 
concentrations of GSI. As a reference, cells transfected with a control siRNA or 
siAPP cells were treated with vehicle (DMSO).  
E. Western blot analysis of the specified proteins and phosphoproteins in total 
cell lysates obtained from cell line H1299 48 hours after transfection, either with a 
control siRNA or a siRNA to APP. Similar results were obtained in multiple 
experiments and in cell line A549. 
Adapted from Sobol et al., 2015 [1]. 
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We hypothesized that one of the known signaling pathways downstream 
of APP could be involved in the regulation of 4E-BP1 phosphorylation. It has 
been demonstrated that APP signaling contributes to the activation of MAPK and 
AKT pathways. Activation of MAPK is mediated by the interaction of GRB2 and 
the C terminus of APP (Nizzari et al., 2007). AKT, on the other hand, is activated 
by oligomers of βeta-amyloid, one of the possible cleavage products of APP (Lee 
et al., 2009). Activation of both of these pathways results in the inactivation of 
tuberous sclerosis 1 and 2 (TSC1/TSC2), upstream inhibitors of mTORC-1. 
Thus, either pathway could mediate the change of 4E-BP1 phosphorylation 
downstream of APP. 24, 48, and 72 hours after APP depletion, MAPK activation 
was reduced as determined by measurement of decreased phosphorylation of 
ERK at T185/187 (Figure 11A). In the same experiments, phosphorylation of AKT 
(at either T308 or S473 residues) was unchanged (Figure 11B, C). While the 
T37/46 residue of 4E-BP1 is mainly phosphorylated by mTORC-1, the 
phosphorylation of S65 and T70 may be mediated by ERKs and cyclin-
dependent kinase 1 (CDK-1; Heesom et al., 2001; Herbert et al., 2002). To 
ascertain whether ERKs or CDK-1 could have contributed to the altered 
phosphorylation pattern of 4E-BP1 observed upon APP depletion, we inhibited 
MAPKK (the upstream activator of ERKs) with UO126 and CDK-1 with 
Roscovitine. We confirmed the efficiency of these pharmacological inhibitors by 
assessing the phosphorylation status of ERKs and phosphorylation of a 
downstream target of CDK-1, wee 1. Phosphorylation of ERKs and wee 1 was 
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reduced after treatment with UO126 and Roscovitine, respectively (Figure 11D, 
E). However, neither ERKs nor CDK-1 inhibition could recapitulate the 
phosphorylation pattern of 4E-BP1 resulting from APP downregulation (Figure 
11D, E). We only observed a decreased phosphorylation of the S65 and T70 
residues upon administration of either UO126 or Roscovitine, but no effect on 
T37/46 was detected. This suggested that APP might alter the 4E-BP1 
phosphorylation pattern (at least in part) through its effects on ERK’s activation, 
but other molecular players awaited identification. Nonetheless, the empirical 
evidence collected thus far allowed us to exclude AKT involvement in these 
phenomena. 
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Figure 11. APP regulates ERKs activity but does not affect AKT 
phosphorylation status.  
A-C. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1299 cells after transfection with a control siRNA (c) 
or siRNA against APP. Similar results were obtained in cell lines A549 and 
H1437.  
D. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1299 cells after 48 hours exposure to vehicle (c) or 
roscovitine (Rosc.). 
E. Same as (D) but cells were treated with UO126 for 24hours.  
Adapted from Sobol et al., 2015 [1]. 
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Screening for potential genes expression alterations caused by APP 
depletion 
 
As previously mentioned, 4E-BP1 phosphorylation at T37/46 was reduced 
upon overexpression of AICD (Figure 10A). AICD is known to interact with Fe65, 
histone acetylransferase Tip60, or eukaryotic transcriptional mediator complex 
MED12, among other proteins, to transcriptionally regulate expression of a large 
number of genes (Gao and Pimplikar, 2001; Turner et al., 2011; XU at al., 2011). 
We hypothesized that a putative transcriptional target of APP (still unidentified) 
could mediate the observed change on 4E-BP1 phosphorylation at T37/46. To 
identify these targets of APP, we performed a genome-wide RNA expression 
analysis. We transfected two NSCLC cell lines (H1299 and A549) with either 
control siRNA or siRNA against APP and subjected them, along with mock 
transfected cells, to the Illumina HumanHT12 array (48,000 probes, RefSeq plus 
EST). The experiment was performed three times in independent fashion. We 
looked for genes, with expression that would decrease at least by half or 
increase at least two fold after APP depletion in both cell lines. Among the vast 
number of genes with alter expression, we identified 17 genes in which 
expression was altered in both cell lines and followed a similar pattern (e.g., 
either upregulated or downregulated in both cell lines). This subset was first 
identified with the mRNA arrays and the results were confirmed using Q-PCR 
(Figure 12A, B). 
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Figure 12. Expression levels of 17 genes changed after APP 
downregulation in two NSCLC cell lines.  
A. Genes with expression level changes upon APP depletion in two NSCLC cell 
lines (H1299 and A549) as determined by the Illumina gene array experiments. 
This table summarizes the ratio of expression between siAPP and control 
transfected cells. Purple highlights indicate those genes that were downregulated 
with commercially available siRNAs in follow-up experiments. 
B. mRNA levels measured using Q-PCR; the experiments were performed on 
total RNA extracted from A549 and H1299 cells transfected with either a control 
siRNA or a siRNA to APP. Columns represent averages; bars represent S.D. The 
mRNA abundance for cells transfected with control siRNA (c) was arbitrarily set 
to 1 at 48 hours after transfection. 
Adapted from Sobol et al., 2015 [1].	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STYX is the downstream target of APP regulating 4E-BP1 phosphorylation 
at T37/46 
 
We used siRNAs that were commercially available and downregulated 14 
genes in which expression changed upon APP depletion in a similar fashion in 
both H1299 and A549. We also decided to artificially downregulate those genes 
whose expression was increased upon APP depletion under the assumption that 
if these genes could have potentially affected 4E-BP1 phosphorylation, their 
modified expression level would have resulted in altered T37/46 phosphorylation 
in some way. First, we confirmed downregulation efficiency with gene-specific 
primers and Q-PCR (data not shown). Next, we assessed if downregulation of 
any of the genes could affect phosphorylation status of 4E-BP1 measuring the 
phosphorylation status of T37/46 by Western blot analysis. Out of all 14 genes 
that we downregulated, only one gene affected the phosphorylation status of 4E-
BP1. This gene encodes the pseudophosphatase STYX. We depleted STYX in 
NSCLC cell lines using two independent siRNAs. Due to the lack of antibodies 
capable of detecting endogenous levels of STYX at the time of the study, we 
confirmed the downregulation efficiency at the mRNA level (Figure 13A). siRNA-
mediated downregulation of STYX increased 4E-BP1 phosphorylation at T37/46. 
Notably, it did not affect the phosphorylation status of two other residues of 4E-
BP1 (Figure 13B). These results seemed to support the idea that STYX is a 
transcriptional target of APP directly involved in the regulation of 4E-BP1 
90 
 
 
phosphorylation at T37/46. To confirm this, we overexpressed the full-length APP 
and found that mRNA levels of STYX increase in three different NSCLC cell lines 
(Figure 13C). Additionally, we observed that when downregulating either APP or 
STYX alone, similar increases in 4E-BP1 phosphorylation at T37/46 were 
measured. However, when we co-transfected cells with both siRNA against APP 
and STYX, we observed an additive effect on phosphorylation of T37/47 (Figure 
13D, compare lanes 1 through 4). Transfection of AICD alone decreased 4E-BP1 
phosphorylation at T37/46 (lanes 5 and 6), but co-transfection of cells with siRNA 
against STYX and AICD partially reversed this change (lanes 7 and 8).  
In conclusion, the results supported the idea that the increase in 4E-BP1 
phosphorylation at T37/46, seen upon APP depletion, is regulated (either directly 
or indirectly) by STYX, which seems to be a bona fide APP transcriptional target.  
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Figure 13. STYX regulates 4E-BP1 phosphorylation at T37/46.  
A. STYX mRNA in H1299 cells transfected with a control siRNA (c) or with the 
indicated siRNAs to STYX (siSTYX2, siSTYX3) as assessed by Q-PCR. 
Columns represent averages of three independent experiments while bars 
represent S.D. The mRNA abundance for cells transfected with control siRNA (c) 
was arbitrarily set to 1 at 48 hours after transfection. We did not assess the 
STYX protein levels because an antibody against endogenous STYX was 
unavailable at the time of the study.  
B. Western blot analysis of the indicated proteins and phosphoproteins 48 hours 
after transfection of the indicated siRNAs.  
C. Q-PCR of STYX mRNA in cells transfected with the control plasmid pCAX (c) 
or with APP 695 cloned in pCAX (APP695). Columns represent averages of 
independent experiments performed in A549, H1299, and H1650 cells; bars 
represent S.D. The mRNA abundance for cells transfected with control siRNA (c) 
was arbitrarily set to 1 at 48 hours after transfection. 
D. Western blot analysis of the indicated proteins and phosphoproteins in H1299 
48 hours after transfection with the indicated nucleic acids. Lanes:  
1, cells transfected with siRNA control (c);  
2, cells transfected with siRNA to APP (siAPP);  
3, cells transfected with siRNA to APP and siRNA to STYX (siAPP+siSTYX);  
4, cells transfected with siRNA to STYX (siSTYX);  
5, cells transfected with control plasmid (pc);  
6, cells transfected with a plasmid encoding AICD (AICD);  
7, cells transfected with control plasmid and siRNA to STYX (pc+siSTYX);  
8, cells transfected with a plasmid encoding AICD and with siRNA against STYX 
(AICD+siSTYX). 
Adapted from Sobol et al., 2015 [1]. 
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APP DEPLETION ALTERS THE COMPOSITION OF THE TRANSLATION 
INITIATION COMPLEX eIF4F 
 
Hyper-phosphorylated 4E-BP1 is thought to release the cap binding 
protein eIF4E, allowing the formation of the translation initiation complex (eIF4F) 
on the 5’ end of mRNA (referred to as cap; Jackson et al., 2010). We asked if the 
4E-BP1 phosphorylation pattern observed upon APP depletion could affect the 
formation/composition of the eIF4F complex. We addressed this question in pull-
down assays using the cap analog, 7-methylguanosine, conjugated to Sepharose 
resin. We analyzed the binding of translation initiation factors to the cap analog 
upon siRNA-mediated APP depletion. We specifically looked at the recruitment of 
the cap binding protein eIF4E, the ATP-dependent RNA helicase eIF4A, the 
scaffolding protein eIF4G, and also the binding of 4E-BP1. The binding of 4E-
BP1 to the cap decreased after APP downregulation (Figure 14A). Reduced 4E-
BP1 to the cap is generally considered an indication of enhanced rate of cap-
dependent protein synthesis (Thoreen et al., 2012). We also detected a 
significant increase in the recruitment of eIF4A to the cap in APP depleted cells 
(Figure 14A). The fact that increased recruitment of eIF4A to the initiation 
complex was not accompanied by an increase of other translation initiation 
factors is not surprising. It has been demonstrated that the binding of eIF4E and 
eIF4A to eIF4G is anti-cooperative and that eIF4A alone can enhance the 
stability of translation initiation complexes (LeFebvre, 2006). 
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Additional evidence that APP depletion affects the activity and/or 
recruitment of eIF4A helicase to the eIF4F complex 
 
eIF4A, a helicase that unwinds secondary structures of mRNA, is 
essential for the initiation of translation. To investigate a potential role of APP in 
the regulation of eIF4A recruitment to the cap, we used commercially available 
inhibitors of eukaryotic protein synthesis. One example is silvestrol, which 
prevents the binding of eIF4A to the initiation complexes and thus inhibits 
translation initiation (Liu et al., 2012). We measured the effect of silvestrol 
treatment on the protein synthesis rate in APP-depleted cells. The rate of protein 
synthesis was measured by incorporation of the methionine surrogate, L-
azidohomoalanine (AHA), which was analyzed by flow cytometry. AHA was 
added to cells along with inhibitors. In the case of complete initiation inhibition, 
AHA is incorporated only into polypeptide chains translated from already pre-
initiated mRNAs. If initiation is not completely inhibited, additional AHA 
incorporation into newly synthesized proteins may be measured. Interestingly, 
APP depleted cells seemed resistant to both partially and completely inhibitory 
concentrations of silvestrol (Figure 14 B, C). The incorporation of AHA by these 
cells was greater than in control siRNA transfected cells treated with silvestrol. 
The efficiency of the inhibitors in decreasing protein synthesis rate was confirmed 
by AHA incorporation in DMSO treated cells (Figure 14D). 
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These experiments supported the hypothesis that APP depletion may alter 
the eIF4F composition by altering eIF4A activity and/or recruitment to the eIF4F 
complex. The fact that APP regulates protein synthesis initiation and not 
elongation was confirmed by a control experiment in which APP-depleted cells 
were treated with homoharringtonine, which blocks translation elongation 
(Tujebajeva et al., 1989; Kantarjian et al., 2001). The incorporation of AHA in 
cells treated with homoharringtonine was inhibited regardless of the absence or 
presence of APP. Cells showed only autofluorescence similar to what was 
observed in cells not exposed to AHA (Figure 14B). Collectively, the experiments 
presented here supported our hypothesis that APP regulates protein synthesis at 
the level of translation initiation, most likely by the regulation of eIF4A 
recruitment. 
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Figure 14. Downregulation of APP results in rearrangements of the 
translation initiation complex on the mRNA cap.  
A. Representative Western blot analysis of the indicated proteins in total cell 
lysates (cell lys.) and in 7-methylguanosine(m7G)-Sepharose pulled-down 
obtained from H1299 cells transfected with either a control siRNA (c) or a siRNA 
against APP (siAPP). Seph. Beads corresponds to Sepharose beads alone (the 
negative control in the pull-down assay). Similar results were obtained in multiple 
experiments and in cell line A549.  
B. Click-iT AHA (L-azidohomoalaine) incorporation assay at the indicated time-
points of cells transfected with either a control siRNA (c) or a siRNA against APP 
and exposed to 100nM silvestrol or homoharringtonine (homohar.). Cells were 
exposed to antibiotics alongside AHA. Geometric means of AHA incorporation 
histograms are presented as acquired by the FlowJo software. 
C. As in (B) but cells were exposed to 40nM silvestrol.  
D. As in (B), but cells were treated with vehicle only (DMSO). This is an example 
of a control experiment (no inhibitor treatment) that was performed alongside the 
experiments with silvestrol or homoharringtonine. The graphs summarize three 
experiments performed in A549 cells. Similar results were obtained in H1299 
cells. Bars represent S.D. 
Adapted from Sobol et al., 2015 [1]. 
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APP REGULATES THE RATE OF PROTEIN SYNTHESIS 
 
Increased phosphorylation of 4E-BP1 and enhanced recruitment of eIF4A 
to the cap, both observed upon APP depletion, led to the hypothesis that APP 
may play a role in the regulation of protein synthesis. Using the AHA 
incorporation assay, we showed that the rate of protein synthesis increases 
significantly upon downregulation of APP (Figure 15A, B). The increase in protein 
synthesis rate was observed not only in different NSCLC cell lines but also in a 
mesothelioma cell line (ME16), in immortalized human keratinocytes (HaCat), 
and in primary human lung fibroblasts (WI-38) (Figure 15C).  
To determine whether a change on protein synthesis observed upon APP 
depletion is physiologically relevant, we compared it to the increase of protein 
synthesis observed in cells that were serum-starved overnight and then 
stimulated with insulin (Figure 15D). Insulin is a potent activator of protein 
synthesis (Proud, 2006). It increases the rate of translation by activating the 
AKT/mTOR signaling pathway. It also activates translation initiation factor eIF2B 
allowing for the recycling of eIF2 to GTP-bound eIF2, which, along with 
methionyl–transfer RNA and 40S ribosomal subunit, forms a ternary complex 
required for translation initiation (Proud, 2006). We first cultured cells overnight in 
media supplemented with 1% fetal bovine serum (FBS). The next day, we 
stimulated these cells with different concentrations of insulin and performed AHA 
incorporation assays. Notably, the increase of AHA incorporation upon APP 
depletion was comparable to the increase observed after insulin stimulation as 
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assessed by the FlowJo software (Figure 15D). The magnitude of the increase 
supports the global nature of the translation regulation by APP. 
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Figure 15. APP regulates protein synthesis  
A. Representative histogram of flow cytometry analysis of the methionine analog 
AHA (L-azidohomoalanine) incorporation in A549 cells transfected with either a 
control siRNA (c, red) or siRNA against APP (siRNA, blue).  
B. The average geometric mean of AHA incorporation in NSCLC cell lines A549, 
H1299, and H1650 as quantified by FlowJo (flow cytometry analysis software). 
Columns represent averages, bars represent S.D.  
C. Depletion of APP results in the increase of protein synthesis in cells of 
different origin. Percentage increase in the geometric mean of AHA 
incorporation. Average with S.D. is presented for three independent experiments 
in specified cell lines.  
D. APP-mediated increase in protein synthesis is comparable to the effect of 
insulin stimulation. AHA incorporation of H1299 cells treated with vehicle DMSO 
(c, red) or stimulated with either 10 nM (blue) or 100 nM (green) of insulin for two 
hours. Negative control, no AHA (black, dotted line). 
Adapted from Sobol et al., 2015 [1]. 
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Eukaryotic mRNAs can be translated via cap or internal ribosome entry 
sequence (IRES) dependent mechanisms. Importantly, eIF4A was shown to be 
required for both modes of translation initiation (Komar and Hatzoglou, 2011). 
Since, we observed that APP depletion interferes with eIF4A activity/recruitment, 
we hypothesized that APP may regulate both modes of translation initiation. To 
test this hypothesis, we co-transfected NSCLC cells with either a control siRNA 
or siRNA against APP and a bicistronic vector which allows for cap dependent 
translation of Renilla luciferase and cap independent (IRES) translation of firefly 
luciferase. Bioluminescence results showed that APP depletion resulted in 
enhanced Renilla and firefly luciferase activities (Figure 16A). We confirmed our 
hypothesis and concluded that APP regulates both cap- and IRES- dependent 
protein synthesis in dividing cells of different origin.  
The effect on protein synthesis observed upon APP depletion was 
reversed by the overexpression of AICD, which is known to interact with more 
than 20 cellular proteins and to regulate transcription of many different targets 
(Figure 16 B; Beckett et al., 2012).  
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Figure 16. APP depletion increases cap- and IRES-dependent translation 
initiation. AICD overexpression results in a decrease of protein synthesis. 
A. The average bioluminescence of cells co-transfected with either a control 
siRNA (c) or siRNA against APP (siAPP) and a bicistronic vector encoding 
Renilla luciferase (representative of cap dependent translation) or firefly 
luciferase (representative of IRES dependent translation). The vector contains 
poliovirus IRES (see Material and Methods for details). Average of 9 experiments 
is presented. Bioluminescence was normalized for the expression of the plasmid 
DNA using luciferase specific primers and Q-PCR.  
B. AHA incorporation in H1299 cells transfected with a control plasmid or the 
plasmid expressing AICD. Cells transfected with DNA show overall lower AHA 
incorporation as compared to cells transfected with siRNAs. 
Adapted from Sobol et al., 2015 [1]. 
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Regulation of protein synthesis by APP does not depend on mTOR 
signaling	  
 
Phosphorylation of 4E-BP1 at T37/46 is catalyzed by the mTORC-1 
complex, a major regulator of protein synthesis (Proud, 2006). In response to 
intra- and extracellular cues, mTORC-1 regulates translation initiation (Jackson 
et al., 2010). It is a checkpoint where decision the cell makes a decision whether 
or not it should engage in anabolic processes. Considering our initial hypothesis 
that mTORC-1 activity could be reactivated by GSI treatment and that deletion of 
APP resulted in increased 4E-BP1 phosphorylation at T37/46, we further 
hypothesized that mTORC-1 could also be involved in the regulation of protein 
synthesis by APP. However, most of the experimental evidence presented below 
suggested that regulation of protein synthesis by APP is independent of mTOR 
signaling, which consequently allowed us to reject our hypothesis.  
First, the phosphorylation of 4E-BP1 observed upon APP depletion seems 
to be mediated by downregulation of the pseudophosphatase STYX (Figure 13). 
Second, APP depletion had no effects on AKT activation, as we did not observe 
any changes on T308 nor S473 phosphorylation (Figure 11B, C). Third, we 
measured the phosphorylation status of one of the canonical mTORC-1 
downstream targets, S6 kinase (p70 S6K), which modulates protein synthesis via 
phosphorylation of multiple targets (eIF4B, PDCD4, CBP80, eEF2A, etc.; 
Laplante and Sabatini, 2012). We observed no change in phosphorylation of p70 
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S6K and S6 protein after APP depletion (Figure 17A). Finally, to further 
investigate the role of mTORC-1 in the regulation of protein synthesis by APP, 
we used a commercially available, specific inhibitor of mTOR kinase’s catalytic 
activity, Torin-1 (Thoreen et al., 2012). 48h exposure of NSCLC cells to Torin-1 
suppressed mTORC-1 activation, as seen by abolished phosphorylation of two 
mTORC-1 targets: 4E-BP1 and S6K (Figure 17B, left). Torin-1 treatment also 
abolished protein synthesis, as seen by inhibited AHA incorporation (Figure 17B, 
right). At this stage, about a third of Torin-1 treated cells underwent cell death. 
Interestingly, even under these harsh inhibitory conditions, the protein synthesis 
rate of APP depleted cells exposed to Torin-1 increased as compared to Torin-1 
treated cells transfected with a control siRNA (Figure 17C). For these reasons, 
we concluded that APP’s effect on protein synthesis is mostly independent on 
mTORC-1 activity. 
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Figure 17. Regulation of protein synthesis by APP is independent of mTOR 
signaling.  
A. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1299 cells transfected with either indicated siRNAs or 
plasmid DNA.  
B. Treatment with Torin-1 suppresses mTORC-1 activity and inhibits protein 
synthesis rate. Left: Western blot analysis of the indicated proteins and 
phosphoproteins in total cell lysates obtained from H1299 cells treated with 
vehicle DMSO (c) or Torin-1. Right: AHA incorporation in H1299 cells treated 
with DMSO (c) or Torin-1.  
C. Incorporation of AHA in H1299 cells transfected with a control siRNA and 
exposed to DMSO (red), transfected with siRNA against APP and exposed to 
DMSO (blue), transfected with a control siRNA and exposed to Torin-1 (light 
green), and transfected with siRNA against APP and exposed to Torin-1 (light 
brown).  
D. Percentage increase in the AHA incorporation as assessed by geometric 
mean acquired with the FlowJo software. Average with S.D. is presented for 
three independent experiments in specified cell lines. 
Adapted from Sobol et al., 2015 [1]. 
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Finally, APP has a close homolog, APLP-2, with which it shares not only 
sequence homology but also tissue-specific distribution pattern (Aydin et al., 
2012). We investigated whether the observed phenotype of protein synthesis is 
specific to APP or if APLP-2 may also be involved in the regulation of translation. 
We transfected cells with siRNAs against either APP or APLP-2. Utilizing Q-PCR, 
we showed that downregulation of APP does not affect the mRNA levels of 
APLP-2 and confirmed downregulation efficiency in cells transfected with siRNA 
against APLP-2 (Figure 19A). Notably, unlike depletion of APP, the 
downregulation of APLP-2 gene did not affect AHA incorporation as compared to 
relevant controls (Figure 19B). 
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Figure 18. APP’s homolog APLP2 does not play a role in regulation of 
protein synthesis rate.  
A. mRNA levels obtained with Q-PCR experiments and performed on total RNA 
extracted from H1299 cells transfected with indicated siRNAs. Columns 
represent averages; bars represent S.D. The mRNA abundance for cells 
transfected with control siRNA (c) was arbitrarily set to 1. 
B. AHA incorporation in H1299 cells 48h after transfection with a control siRNA 
(c) and siRNA against APP (siAPP, left) or siRNA against APLP2 (siAPLP2, 
right). 
Adapted from Sobol et al., 2015 [1].	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In conclusion, APP inhibits protein synthesis via regulation of different 
signaling pathways like ERKs and STYX. It also regulates the recruitment of 
eIF4A to the initiation complex, thus affecting both cap- and IRES-dependent 
translation initiation. Based on the results from several experiments, we 
concluded that the regulation of protein synthesis by APP is mTORC-1 
independent. Finally, considering the pleiotropic effect of the APP protein, we 
cannot exclude additional downstream effectors of APP signaling may also be 
involved in the observed phenotype.  
 
APP DEPLETION LEADS TO THE ARREST OF NSCLC CELLS IN G0 PHASE 
OF THE CELL CYCLE 
 
We have elucidated that APP regulates translation initiation. Protein 
synthesis is one of the most important processes undertaken by a cell and is 
closely associated with cell growth and proliferation. It has been accepted that 
the rate of protein synthesis increases linearly during cell division (Baxter and 
Stanners, 1978). Progression through the cell cycle depends on many factors, 
including the availability of nutrients and growth factors. As an example, 
Receptor Tyrosine Kinases (TKR) can transduce growth factor stimulation to 
activate both MAPK and PI3K/AKT/mTOR pathways, which consequently lead to 
the activation of protein synthesis (Laplante and Sabatini, 2012). During the G1 
phase of the cell cycle, cells have to clear the dominant, nutrient-dependent 
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restriction point that corresponds to START in yeast (Fingar and Blenis, 2004). 
Thus, it appears that at this point during cell division the major synchronization 
between cell growth and cell cycle progression takes place. This synchronization 
is very important for cell homeostasis, as inhibition of protein synthesis leads to 
cell death while excessive protein translation results in deregulated proliferation 
and tumor-like outgrowth (Lindqvist et al., 2012). Recent discoveries also showed 
that genetic changes affecting the translation machinery are associated with 
cancer susceptibility, with this phenomena described as “ribosomopathies” 
(Ruggero, 2013). Thus, translational rate and cell growth are two interdependent 
cellular processes. 
Since we have noticed that protein synthesis increases significantly upon 
APP depletion, we hypothesized that APP could affect cell cycle progression and 
cell growth. We transfected NSCLC cells with either a control siRNA or siRNA 
against APP and stained DNA of permeabilized cells with propidium iodide. Flow 
cytometry analysis revealed the accumulation of cells in the G0/G1 phase of the 
cell cycle upon APP depletion (Figure 20B).  
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Figure 19. APP depletion causes G0/G1 arrest and decreases cell 
proliferation.  
A. Representative Western blot analysis of the indicated proteins in total cell 
lysates obtained from NSCLC cells transfected with either a control siRNA (c) or 
siRNA against APP (siAPP).  
B. Propidium iodide (PI) cell cycle staining of NSCLC cells (representative of 
three experiments in: top panel, A549; middle panel H1299; bottom panel, 
H1437) transfected with a control siRNA (c, left) and with a siRNA against APP 
(siAPP, right). Numbers represent percentage of cells in each phase of the cell 
cycle as determined by FlowJo analysis using the Watson pragmatic model. The 
observed changes were reproducible and statistically significant. 
Adapted from Sobol et al., 2015 [2].	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To analyze cell proliferation, we used bromodeoxyuridine (BrdU) 
incorporation assays. Total DNA was stained with 7-aminoactinomycin D (7-
AAD) and analysis was made using FACS. This assay revealed that APP’s loss 
of function reduces the percentage of proliferating cells (Figure 21). Decreased 
proliferation and cell cycle arrest observed upon APP depletion were 
reproducible in all NSCLC studied and in normal lung fibroblasts, although to a 
lower extend (Figure 21).  
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Figure 20. APP depletion reduces the fraction of cells that replicate DNA. 
Bromodeoxyuridine (BrdU) incorporation followed by flow cytometry analysis of 
indicated cells transfected with a control siRNA (left) and a siRNA against APP 
(right). Representative of three independent experiments is shown. The observed 
changes were reproducible in cells of different origin and were statistically 
significant. 
Adapted from Sobol et al., 2015 [2]. 
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Furthermore, we wanted to determine whether APP depletion causes 
accumulation of cells in either G0 or G1 phase of the cell cycle. To discriminate 
between the two, we used the acridine orange (AO) staining, which differentiates 
between the dsDNA and ssRNA content of the cells (Darzynkiewicz et al., 2004). 
We assessed that cells transfected with siRNA against APP had a 13.8±3.5 fold 
increase in the G0 fraction compared to cells transfected with a control siRNA 
(Figure 22A). AO staining does not accurately set a boundary between cells in S 
and G2/M phases. However, it allowed us to identify a new cell population that 
was present within APP depleted cells. This population consisted of cells that 
stained negatively for both DNA and RNA content but with a size similar to cells 
in G0 or G1 phase of the cell cycle. We named this population “sub-G0”. To 
analyze the “sub-G0” cells in more detail, we used an Amnis Image StreamX 
imaging flow cytometer. Analysis of images of these cells demonstrated that they 
lack nuclei. It appears that these cells could be necrotic (Figure 22B).  
In conclusion, APP seems to synchronize protein synthesis rate and cell 
cycle progression and its loss results in what appears to be necrotic cell death. 
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Figure 21. APP depletion causes G0 arrest and cell necrosis.  
A. Acridine orange (AO) staining of A549 cells transfected with a control siRNA 
(c, left) or siRNA against APP (siAPP, right).  
B. Amnis Image StreamX imaging flow cytometer analysis of siRNA against 
APP-transfected H1299 cells. Left: gating of cell populations; Right: bright field 
and fluorescence images of representative cells from each cell population. 
Original magnification 40X. Same results were obtained in A549 and H1650 
cells. 
Adapted from Sobol et al., 2015 [2]. 
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APP mediated G0 arrest involves cyclin C destabilization 
We wanted to clarify which downstream target(s) of APP may be involved 
in the observed cell cycle arrest. We already confirmed that loss of APP results in 
the inhibition of MAPK pathway (Figure 11A), a well-established regulator of cell 
proliferation (Zhang and Hui, 2002). Inhibition of ERKs but also cyclin dependent 
kinases (CDK), which regulate cell cycle progression, could contribute to the 
changes observed upon APP downregulation. Thus, we inhibited the MAPK 
pathway using UO126 and CDK-1/CDK-2 using roscovitine (Schutte et al., 1997). 
However, treatment of hypoxic NSCLC cells with the aforementioned inhibitors 
did not recapitulate the cell cycle distribution observed after APP depletion. 
Treatment with roscovitine resulted in a G2/M arrest, while treatment with UO126 
resulted in the arrest of cells in G1 phase of the cell cycle with no apparent 
accumulation of cells in the G0 phase (Figure 23A-D). 
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Figure 22. Inhibition of CDKs and ERKs does not recapitulate cell cycle 
distribution observed upon APP depletion.  
A. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1299 cells treated with a vehicle control (c, DMSO) or 
roscovitine (Rosc.) Cdk1 mediated phosphorylation of wee1 served as positive 
control for the roscovitine treatment.  
B. PI staining of H1299 cells treated as in (A).  
C. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1437 cells treated with a vehicle control (DMSO, c) or 
UO126. Phosphorylation of ERK served as positive control for the UO126 
treatment.  
D. PI staining of H1437 cells treated as in (C).  
E: AO staining of H1437 treated as in (C). Please note that neither UO126 nor 
roscovitine treatment generated the “sub-G0” population of necrotic cells.  
Adapted from Sobol et al., 2015 [2]. 
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To find possible mediator(s) of G0 arrest induced by APP depletion, we 
used commercially available antibody arrays, including a large number of 
proteins and phosphoproteins known to regulate cell cycle. We looked for 
changes caused by APP downregulation common to two NSCLC cell lines 
(H1299 and A549). The only apparent changes that have been observed 
included a modest decrease in cyclin E and a 2.5 fold decrease in cyclin C 
protein expression levels. We investigated the protein and mRNA levels of both 
cyclins by Western blot and Q-PCR analysis in cells after APP depletion. Cyclin 
E was reduced at both protein and mRNA level 48 hours after siRNA-mediated 
APP downregulation. On the other hand, while mRNA levels of cyclin C remained 
the same, its protein levels were reduced at every time point after siRNA to APP 
transfection, with these outcomes reproducible in different cell lines (Figure 24A, 
B). Cyclin C protein expression changes are consistent with the timing of APP 
depletion-induced cell cycle arrest. We hypothesized that cyclin C is a target of 
APP involved in the G0/G1 arrest.  
Cyclin C is known to bind CDK8 and contribute to the phosphorylation of 
the carboxy-terminal domain (CTD) of RNA polymerase II (Rickert et al., 1996). 
More importantly, a second pool of cyclin C binds CDK3 and controls G0 to G1 
progression. Cyclin C-bound CDK3 phosphorylates the retinoblastoma protein 
(pRb) at S807/811 allowing cells to exit G0 phase of the cell cycle (Ren and 
Rollins, 2004). It has also been determined that cyclin C (at least in yeast) is a 
short-lived protein and is possibly degraded via the ubiquitin–proteasome system 
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(Hautbergue and Goguel, 1999). Notably, we only observed changes in protein 
and not mRNA levels of cyclin C upon APP depletion. This implies that APP may 
regulate cell cycle progression via destabilization of cyclin C protein levels. To 
test this hypothesis, we immunoprecipitated cyclin C from cells transfected with 
either a control siRNA or siRNA against APP and blotted for cyclin C and 
ubiquitin. We performed this experiment in the presence of proteasomal inhibitor, 
MG132. We investigated if total levels and ubiquitination of cyclin C could be 
affected by APP levels and if APP can mediate cyclin C degradation via the 
proteasome mediated mechanism. In the absence of MG132, only about 25% of 
cyclin C was immunoprecipitated from cells depleted of APP as compared to 
control cells (Figure 24C). We also observed a more intense smear when blotting 
these immunoprecipitates for ubiquitin as compared to the relevant control 
(Figure 24D). When transfected cells were treated with MG132, equal amounts of 
cyclin C were immunoprecipitated from both control and APP depleted cells 
(Figure 24E). The change in the migration of Cyclin C upon MG132 treatment 
resulted from ubiquitin moieties added to cyclin C. We expected to find bands at 
higher molecular weight. However, this situation is extremely common when 
immunoprecipitating any protein and then blotting for the same protein. This 
phenomenon has been attributed to “ubiquitin depletion” caused by prolonged 
MG132 exposure (Kim et al., 2011). In conclusion, we have found that APP 
regulates the stability of cyclin-C via polyubiquitination and proteasome mediated 
degradation.
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Figure 23. APP depletion causes proteasome-mediated cyclin C 
degradation.  
A. Q-PCR analysis of the indicated mRNAs in A549, H1299 and H1650 
transfected with a control siRNA (c) or with a siRNA against APP (siAPP). 
Columns represent averages, bars S.D. The mRNA abundance for cells 
transfected with control siRNA (c) was arbitrarily set to 1. 
B. Western blot analysis of the indicated proteins and phosphoproteins in total 
cell lysates obtained from H1299 cells transfected with control siRNA (c) or 
siRNA against APP (siAPP) at the indicated time-points. Similar results were 
obtained in A549, H1650 and H1437 cells.  
C. Immunoprecipitation of cyclin C in H1299 transfected with a control siRNA (c) 
or siRNA to APP (siAPP). IgG; irrelevant immunoglobulin G.  
D. Same as (C), but membrane was blotted with an antibody against ubiquitin.  
E. Same as (C), but H1299 cells were treated with the proteasomal inhibitor 
MG132 for 24 hours prior to immunoprecipitation.  
Adapted from Sobol et al., 2015 [2]. 
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Depletion of cyclin C reproduces the cell cycle distribution observed upon 
APP depletion. Overexpression of AICD reverses this phenotype 
 
We assessed if APP depletion affects the phosphorylation status of pRb. 
We performed experiments with a control siRNA or siRNAs against either APP or 
cyclin C. Depletion of both APP and cyclin C resulted in a similar decrease in 
phosphorylation of the S807/811 residues (Figure 25A). Moreover, when blotting 
for cyclin C, we noticed the disappearance of a band corresponding to the cyclin 
C isoform associated with the G0 exit in yeast (Hautbergue and Goguel, 1999). 
Using AO staining we investigated whether siRNA-mediated depletion of 
cyclin C caused a similar cell cycle distribution as seen after APP 
downregulation. Both G0/G1 arrest and, more importantly, the appearance of the 
“sub-G0” population were observed in cyclin C depleted cells as compared to the 
relevant controls (Figure 25B). These effects were not as strong as with APP 
depletion. We investigated if cyclin C may regulate protein synthesis rate like 
APP. However, we found that cyclin C levels does not affect protein translation 
(not shown). Thus, cyclin C seems to produce some sort of uncoupling of cell 
cycle progression and cell growth (e.g., unaltered rate of protein synthesis 
paralleled by cell cycle arrest). However, this uncoupling is not as severe as after 
APP downregulation, which causes cell cycle arrest and an increase in the rate 
of protein synthesis. This may explain why the percentage of cell death is not as 
high in cyclin C versus APP depleted cells. 
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It seems that AICD is involved in the regulation of protein synthesis rate. 
Thus, we investigated if this APP domain may also be involved in the regulation 
of cell cycle progression. Interestingly, overexpression of AICD increased the 
percentage of proliferating cells and decreased the fraction of necrotic cells as 
visualized by the acridine orange assay (Figure 25C). 
124 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
125 
 
 
Figure 24. Cyclin C depletion mimics and AICD reverses the phenotype 
observed on cell cycle upon APP downregulation.  
A. Western blot analysis of the indicated proteins and phosphoproteins in H1299 
cells transfected with a control siRNA (c), with siRNA against APP (siAPP), or 
with siRNA against cyclin C (sicyclin-c). Similar results were obtained in A549 
and H1650 cells. 
B. AO staining of A549 cells after transfection with a control siRNA (c), or with a 
siRNA against cyclin C (siCycl.C).  
C. AO staining of A549 cells transfected with a control plasmid (pCont) or with a 
plasmid expressing AICD. Similar results were obtained in H1299 cells. 
Adapted from Sobol et al., 2015 [2]. 
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APP DEPLETION RESULTS IN THE INCREASED CELL SIZE OF HYPOXIC 
NSCLC CELLS 
 
APP depletion increases protein synthesis rate and promotes cell cycle 
arrest. We tested the effect that this uncoupling could have on cell growth and 
cell viability. Interestingly, the size of APP depleted cells were larger compared to 
the control cells. We measured a 113-130% increase of cell size 72 hours after 
siRNA transfection, as determined by flow cytometry (Figure 26A). It also 
appeared that the integrity of the cell membrane of APP depleted cells was 
compromised as visualized by PI staining of previously non-permeabilized cells, 
grown in hypoxia and nutrients’ restriction. After APP downregulation, larger 
population of cells stained positive for PI (Figure 26B). 
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Figure 25. The size of APP depleted cells increases and these cells 
undergo necrotic cell death.  
A. Forward light scattering flow cytometry analysis of H1299 cells 72 hours after 
transfection with either a control siRNA (dotted line) or siRNA against APP 
(siAPP, solid line). Similar results were obtained in A549, H1650 and H1437 
cells.  
B. Flow cytometry analysis of PI staining of non-permeabilized A549 cells 72 
hours after transfection with either a control siRNA (left) or siRNA against APP 
(siAPP, right). Cells were grown in reduced serum media (10% FBS media was 
diluted 1/40 in PBS). Similar results were obtained in H1299 and H1650 cells.  
Adapted from Sobol et al., 2015 [2]. 
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Overall, we showed that loss of APP function results in enhanced cell 
growth and G0 arrest of NSCLC cells. This uncoupling between protein synthesis 
rate and cell cycle progression led to increased cell size and necrotic cell death. 
We believe that this paradoxical uncoupling between growth and proliferation 
makes sense for a protein that regulates G0/G1 transition, when rates of high cell 
growth are probably unnecessary and possibly detrimental in yet uncommitted 
hypoxic NSCLC cells (see Discussion). 
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CHAPTER FOUR 
DISSCUSSION 
 
We have demonstrated that loss of APP function produces a number of 
seemingly paradoxical effects. APP depletion leads to G0 arrest and enhanced 
rate of global protein synthesis (both cap- and IRES-dependent). This unique 
dissociation between proliferation and growth causes cellular abnormalities, such 
as increased cell size of NSCLC cells cultured in hypoxic conditions, and ulti-
mately to necrotic cell death. Our data indicate that APP seems to be required for 
G0/G1 transition by preserving cyclin C levels. It also modulates protein synthesis 
rate via pleiotropic effects on different signaling molecules. These include (but 
may not be limited to) ERK kinases and STYX pseudophosphatase that together 
alter phosphorylation status of 4E-BP1, an inhibitor of translation. Additionally, 
regulation of eIF4A function and/or its recruitment to the cap seems to be a major 
contributing factor to the observed changes on the rate of protein synthesis upon 
APP depletion (a schematic summary of these phenomena is reported in Figure 
26). 
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Figure 26. Summary of the findings of this dissertation. APP (through its in-
tracellular domain activity, which, at least in part, includes transcriptional regula-
tion) controls G0/G1 transition and the rate of global protein synthesis. Experi-
mental evidence suggests that APP modifies translation initiation via pleiotropic 
effects including (but not necessary limited to) regulation of ERKs, STYX, and 
eIF4A function and/or its recruitment to the 5’ end of mRNA. On the other hand, 
the APP/AICD promotes transition to the G1 phase of the cell cycle by the regula-
tion of Cyclin C protein levels.  
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APP REGULATION OF PROTEIN SYNTHESIS IN NSCLC CELLS 
 
The RAS/ERK and PI3K/AKT/mTOR signaling pathways, which regulate 
proliferation and cell growth, have been recently shown to converge at the trans-
lation initiation step, specifically on 4E-BP1 phosphorylation status and its ability 
to inhibit eIF4E (She, 2010). It has been shown that 4E-BP1 phosphorylation and 
cap-dependent protein synthesis depend mainly on AKT signaling in malignant 
cells with hyperactive PI3K/AKT. However, malignant transformation also re-
quires the deregulation of RAS/ERK pathway. In all cancer cells tested, 4E-BP1 
is a target of both pathways and inhibition of one pathway alone is not sufficient 
to inhibit 4E-BP1 phosphorylation, cap-dependent translation, cell growth, prolif-
eration, and oncogenicity in vivo (She, 2010). Since our data supports a role for 
APP in the regulation of cell cycle entry and protein synthesis rate, it is not sur-
prising that APP (via ERKs and STYX) ultimately affects 4E-BP1 phosphorylation 
status. This appears to be the point at which the PI3K/AKT and RAS/ERK path-
ways converge, promoting both growth and proliferation of malignant cells (She, 
2010).  
APP depletion resulted in increased phosphorylation at T37/46 and de-
creased phosphorylation at S65 residues of 4E-BP1. ERKs are known to regulate 
S65 and T70 phosphorylation. We found that the pseudophosphatase STYX reg-
ulates phosphorylation at T37/46. This is an entirely novel role for STYX. Alt-
hough sharing sequence and structural similarities with genuine phosphatases, 
STYX is considered a pseudophosphatase because it is catalytically inactive. In-
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stead of cysteine in the catalytic site, required for dephosphorylation, STYX has a 
glycine residue (Wishart et al., 1995). Even though they lack catalytic activity, 
pseudophosphatases are known to regulate different signaling pathways (Tonks, 
2009). STYX itself was shown to be required for spermatogenesis and STYX 
knockout male mice are infertile. STYX binds a testicular RNA-binding phospho-
protein CRHSP-24 that is important during differentiation of spermatids into 
spermatozoa (Wishart and Dixon, 2002). Using a computational modeling based 
approach, STYX was also found to interact with MAPK signaling pathway. STYX 
regulates the nuclear export of ERK1/2 kinases, inhibits their activation, and re-
duces differentiation of PC12 cells (Reiterer et al., 2013). Proteins containing 
STYX (phosphoSerine, phosphoThreonine, or phosphotYrosine) domain proba-
bly evolved from the PTP (protein tyrosine phosphatase) family (Wishart and 
Dixon, 1998). It has been suggested that they retain the ability to bind the phos-
phorylated substrates of proteins with which they interact .The binding of pseu-
dophosphatases to phosphorylated substrates alters, among other properties, 
their cellular localization, substrate selectivity, and binding partner selection. This 
binding also gives these catalytically inactive proteins to ability to signal (Tonks, 
2009). A parallel between pseudophosphatases and 14-3-3 proteins can be 
made. The latter also play important roles in vital cellular processes without pos-
sessing specific catalytic activities. 14-3-3 proteins bind as dimers to phosphory-
lated polypeptides altering their functions substantially (Fu et al., 2000). The ex-
act mechanism by which STYX can affect 4E-BP1 phosphorylation at T37/46 but 
it could bind to these sites directly, thus preventing their de-phosphorylation. Al-
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ternatively, STYX could alter the substrate specificity of ERKs and direct them 
towards T37/46 (besides S65 and T70). Similar types of interactions have been 
described before. For example, it has been suggested that a pseudophosphatase 
TAB1 (TAK1 [transforming growth factor-β-activated kinase 1]-binding protein 1), 
which is a subunit of TAK1, has no catalytic activity but modulates the accessibil-
ity of phosphorylation residues on TAK1 substrates (Conner et al., 2006). Also, a 
pseudophosphatase is involved in cell cycle regulation and Cyclin-CDK (cyclin 
dependent kinase) interactions. Cyclins are well known to alter substrate specific-
ity of the CDKs they associate with or to change their intracellular localization 
(Miller and Cross, 2001; Moore et al., 2003). For example, substrate preference 
differs whether CDK2 is bound to either cyclin E or cyclin A (Schulman et al., 
1998). Alternatively, the mTOR kinase, which is phosphorylated on a variety of 
residues, could be a target of STYX. Rapamycin, an example of a molecule 
which can allosterically alter mTOR activity independently from mTORC-1 classic 
regulation, binds to the FRB domain of mTOR, alongside FKBP12, thus inhibiting 
mTORC-1 independently of stimulatory signals (Laplante and Sabatini, 2009). 
We have been unable to test these hypotheses because efficient antibodies 
against human STYX are just now becoming available. This could explain why 
the scientific literature concerning human STYX includes less than a handful of 
papers. To summarize, the hypotheses that STYX affects substrate specificity of 
ERKs or mTOR should be investigated in future experiments and may have far-
reaching implications. Notably, we have shown that it regulates phosphorylation 
of 4E-BP1 under conditions which should prevent it. This implies that STYX inhi-
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bition alone could resume anabolic processes in tumor environments that are in-
compatible with them. Therefore, inhibiting STYX may have a role in the promo-
tion of necrosis of hypoxic tumor cells. 
We propose that a major contribution to the APP mediated increase in the 
rate of protein synthesis is due to the increased recruitment of eIF4A in pre-
initiation complexes. Additionally, APP depleted cells showed resistance to the 
treatment with silvestrol, a translation initiation inhibitor, which prevents binding 
of eIF4A to the eIF4F initiation complex (Liu et al., 2012). eIF4A, a DEAD-box 
helicase that catalyzes the ATP-dependent unwinding of RNA duplexes 
(Korneeva et al., 2001; for details see section 1.4.2), is essential for both cap-
dependent and IRES-dependent translation initiation (Komar and Hatzoglou, 
2011). The fact that APP regulates both modes of translation initiation further 
strengthen the case that eIF4A may be a downstream target of APP responsible 
for the observed phenotype. The exact mechanism by which APP/AICD regu-
lates eIF4A activity needs to be determined in future studies. However, it is well 
known that the majority of cellular mRNAs harbor long 5’ untranslated regions 
(UTR) that form complex tertiary structures. An increased recruitment of the initi-
ation factor responsible for the unwinding of these structures most likely renders 
the initiation complex more efficient in scanning 5’ UTRs, therefore rendering ini-
tiation (the rate-limiting step in protein synthesis) more efficient. Since regulation 
of translation fundamentally affects the biology of the cell, the role of APP in 
translation initiation regulation warrants further investigation. For example, poly-
some profiling (Faye et al., 2014) could be implemented to determine if APP de-
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pletion in hypoxic NSCLC cells correlates with changes in translation of eukaryot-
ic mRNAs on a global level or only within a subset of eukaryotic mRNAs. These 
mRNAs could be related to a malignant phenotype or to survival in hypoxic envi-
ronment. It is increasingly recognized that “qualitative” regulation of protein syn-
thesis plays a fundamental role in these processes (Ruggero, 2013). eIF4A is be-
ing considered as a therapeutic target for cancer treatment (Grzmil and Hem-
mings, 2012). However, the eIF4A inhibitors developed thus far have proven 
overly toxic and their introduction in clinical settings is lagging. 
 
APP REGULATION OF G0/G1 TRANSITIONS 
 
APP appears to promote cell cycle entry by regulating cyclin C steady-
state expression levels. Cyclin C exists in the cell in two distinct pools: one frac-
tion associates with CDK8 and another associating with CDk3. In this first pool, 
cyclin C associates with CDk8, promoting phosphorylation of the carboxy-
terminal domain (CTD) of RNA polymerase II. This Cyclin C/CDK8 association 
was found to further associate with RNA polymerase II both in vitro and in vivo 
(Rickert et al., 1996), profoundly affecting the general properties of the polymer-
ase. The second pool of cyclin C (which is extremely short-lived; Ren and Rol-
lins, 2004) associates with CDK3 and is required for G1 entry (Rickert et al., 
1996; Ren and Rollins, 2004). We propose that APP selectively regulates the 
stability of this second pool of cyclin C. Firstly, western blot analysis of cyclin C 
upon downregulation of APP showed a band corresponding to a cyclin C isoform 
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that binds CDK3 and regulates cell cycle in yeast (Hautbergue and Goguel, 
1999) is lost. Secondly, if the activity of RNA polymerase II, a major transcrip-
tional regulator (Hahn, 2004), would change in our system due to interference by 
APP on the pool of cyclin C with which it associates with, we would have meas-
ured dramatic changes in gene expression in our Illumina arrays, most likely in 
 both cell lines tested. This hypothesis can be rejected because we observed on-
ly 17 genes with expression which was either increased 2 fold or decreased at 
least by half after downregulation of APP in both NSCLC cell lines. The question 
that still awaits clarification is how APP/AICD signaling selectively regulates Cy-
clin C levels. The pool of cyclin C that associates with CDK3 is phosphorylated at 
specific sites, while CDK8-associated cyclin C is not (Hautbergue and Goguel, 
1999). We speculate that AICD may transcriptionally regulate a component of the 
ubiquitin proteasome pathway involved in Cyclin C degradation (e.g., a specific 
E3 ubiquitin ligase that recognizes a specific pattern of phosphorylation on cyclin 
C). Alternatively, AICD may directly interact with CDK3-associated cyclin C.  
Importantly, does APP act as a regulator of cell growth and proliferation 
only in a nutrient-deprived, hypoxic tumor environment or does it still contribute to 
malignant transformation independently of the microenvironment? There is suffi-
cient literature in the field to propose hypotheses. APP is overexpressed in dif-
ferent types of tumors (Meng et al., 2001; Hansel et al., 2003; Haven et al., 2004; 
Krause et al., 2008; Takayama et al., 2009). These reports would support an on-
cogenic role for APP independently of the tumor environment. However, the 
cleavage of APP (hence, APP signaling) is drastically increased under hypoxia 
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(Wang et al., 2006; Zhang et al., 2007). For this reason, we support the hypothe-
sis that cancer cells in hypoxic microenvironment depend on APP signaling for 
their survival. Increased APP activity in malignant cells under these conditions is 
expected to suppress a process with high energy consumption like protein syn-
thesis to avoid cell death due to energy exhaustion. One should bear in mind that, 
under hypoxia, cancer cells are under a metabolic checkpoint and are actively 
engaging in autophagy (Hu et al., 2012). Therefore, in hypoxic tumor regions 
NSCLC cells may be more dependent on APP signaling compared to the same 
cells located in different environmental conditions. This dependence on APP sig-
naling could be referred to as an “oncogene addiction” (Weinstein and Joe, 2008), 
which in this case, is specific to the hypoxic tumor environment. Regulation of 
cell growth and cell cycle progression could also be a physiological role of APP, 
which is known to produce pleiotropic effects in cells of different origin (Muller 
and Zheng, 2012).  
We did not expect to see cell cycle arrest upon APP depletion because 
the same genetic manipulation led to increased cell growth. Growth and prolifera-
tion are inherently linked processes and their complete dissociation appeared 
paradoxical. This apparent contradiction can be explained by taking into consid-
eration the following traditional observations in cell biology. G0 exit (and G1 entry) 
is promoted by growth factor stimulation. This event leads to a very rapid activa-
tion of the PI3K/AKT and Ras/ERKs pathways. Therefore, one of the earliest 
phenomena that should be observed upon G1 entry should be a “burst” in global 
protein synthesis. This phenomenon has never been observed but takes place 
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gradually through G1 progression (Alberts, 2002). This means that a signaling 
pathway is inhibiting mTORC-1 activity early in G1 and this pathway must follow 
regulatory networks completely independent from the known mTORC-1 regulato-
ry signals. We propose that APP is centrally involved in this finely tuned process. 
APP, which promotes cell cycle progression (G0/G1), will also limit the rate of a 
highly energy-consuming process like protein synthesis in cells that are uncom-
mitted to proliferation. Cells exiting the G0 phase are not fully committed to the 
cell division because they still need to clear important checkpoints, which take 
place in G1 (Fingar and Blenis, 2004; Foster et al., 2010). The Ras/Raf/MEK/ERK 
and the PI3K/PTEN/AKT/mTOR signaling cascades control the restriction point 
and “cell growth” checkpoint, respectively, during the G1 phase of the cell cycle 
(Foster et al., 2010). The nutrient dependent “cell growth” checkpoint, that is 
equivalent to START in yeast, depends on mTOR activity (Foster et al., 2010). 
Activation of the PI3K/AKT/mTORC-1 pathway, upon stimulation of cells with se-
rum, leads to the inhibition of TGF-β signaling, indirectly suppressing the cyclin 
E-CDK2 complex required for the transition from G1 to S phase (Song et al., 
2006; Gadir et al., 2008). At this stage, mTORC-1 signaling may become pre-
dominant over APP signaling. 
Essentially, we propose that APP controls transitioning of cells from G0 to 
G1 phase of the cell cycle while moderating protein synthesis in a stage when cell 
fate has yet to be determined, through an mTORC-1 independent mechanism.  
Uncoupling of cell growth and cell cycle progression (observed upon APP 
depletion) has been described before but it seems to result in cell death. For ex-
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ample, overexpression of p16 (INK4A), an inhibitor of cyclin dependent kinases 
regulating G1 to S phase transition, led to arrest of cells in G1 with a normal pro-
tein synthesis rate. This uncoupling resulted in apoptotic cell death (Ausserlech-
ner et al., 2005). In our cells, APP depletion caused cell cycle arrest (at the G0/G1 
phase) and increased protein synthesis rate. This complete dissociation between 
growth and proliferation led to cell enlargement and necrotic cell death. Just like 
APP, myc and PI3K signaling pathways control cell growth and cell cycle pro-
gression. However, besides the regulation of protein synthesis rate, both path-
ways also regulate neolipogenesis (Laplante and Sabatini, 2009). If APP regu-
lates only protein synthesis, increases in cell size without concomitant synthesis 
of major membrane components would be detrimental for cell membrane integrity 
and the fate of the cell (Dang, 2011; Yecies et al., 2011). If this is the case, then 
necrosis that occurs due to the loss of APP function seems to be unplanned. 
While many studies implicat the role of specific signaling pathways in the regula-
tion of necrotic cell death (Vanden Berghe et al., 2014), it seems that in our sys-
tem necrosis is a result of compromised cell membrane integrity, occuring spon-
taneously.  
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APP MAY PARTICIPATE IN AN EARLY CELL SIZE CHECKPOINT 
 
Evidence indicates that some control mechanisms of cell size, or critical 
size checkpoints, are in place throughout the evolutionary tree within the con-
straints of nutrients availability. This has been somewhat controversial in mam-
malian cells (Marshall et al., 2012). Separating cell growth and proliferation as 
independent processes appears impossible given the mounting evidence from 
the past two decades indicating that growth and proliferation are coupled. A large 
amount of evidence supports a pivotal role for the phosphatidylinositol 3-OH ki-
nase (PI3K)/Akt/mTORC-1 axis in the establishment of this possible crosstalk. 
Studies showed that mutating several components of this signaling pathway in-
fluenced both cell size and number, hence organ size (Böhni et al.,1996; Leevers 
et al., 1996; Goberdhan et al., 1999). Likewise, mutations which inactivate genes 
which lead to deregulated mTORC-1 activity and failed metabolic checkpoints 
cause syndromes which are characterized by multiple tumor-like outgrowths in 
humans, such as Cowden syndrome (Liaw et al., 1997) and tuberous sclerosis 
(Brook-Carter et al., 1994). Conversely, experimental knockout of a number of 
genes heavily involved in PI3K activation and its downstream effectors causes 
organ hypoplasia and reduced body size in mice (Liu et al., 1993; Dummier et al., 
2006). 
Among the gene knockouts (KO) affecting organ and body size, one of the least 
characterized is APP. Mice carrying a homozygous deletion of APP are about 20% 
smaller than their wild type or heterozygous littermates (Zheng et al., 1995). This 
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phenotype has been attributed to a reduced food and liquid intake in APP KO 
mice, a possible result of a functional brain defect in hunger control. Nonetheless, 
the APP KO mouse has a phenotype that closely resembles what has been ob-
served in knockout mice for proteins inherently linked to the coordination of 
growth and proliferation. Traditionally, most of the mammalian cell size check-
points seemed to operate during G2/M. Recently, studies have indicated that cell 
size checkpoints are operating throughout the cell cycle (reviewed in Yasutis and 
Kozminski, 2013). Since depletion of APP leads to an increase in cell size, we 
cannot exclude that APP participates in an early cell size checkpoint. 
 
APP AS A THERAPEUTIC TARGET IN ANTI-CANCER TREATMENT 
 
Often contributing to malignant transformation, signaling molecules that 
regulate both cell cycle progression and cell growth are being pursued in cancer 
research (Sulić et al., 2005). Our findings showed the role of APP depletion in 
mediating necrotic death of cancer cells in hypoxia. Consequently, they provide a 
rationale to target APP signaling pathway in therapies against hypoxic NSCLC. 
 Hypoxia supports cancer stem cell (CSC) maintenance and we showed 
that APP targets hypoxic NSCLC cells. Previous studies implicated a role of APP 
in neural stem cell biology (Kwak et al., 2006). Numerous studies have demon-
strated an intrinsic link between hypoxia and the establishment of CSC niche (re-
viewed in Keith and Simon, 2007). Thus, it would be worthy to see if APP may 
function as a cell growth regulator in cancer stem cells and if its depletion could 
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have any effect on cancer stem cell survival. Alternatively, the eradication of hy-
poxic tumor tissue could deprive NSCLC CSC of their natural niche. The im-
portance of novel ways to target CSC in anti-cancer therapy, would significantly 
improve current treatments and potentially prevent tumor recurrence, cannot be 
underestimated. 
Furthermore, increased expression of translation initiation factors and ge-
netic predisposition resulting in the deregulation of ribosomal components of 
translation machinery are associated with malignant transformation (Ruggero, 
2013). Therefore, anti-cancer therapies targeting the protein synthesis apparatus 
are being extensively investigated (Grzmil and Hemmings, 2012). Most of the 
drugs targeting deregulated protein synthesis are mTOR inhibitors (Wander et al., 
2011). Some of them were found to be effective as anti-cancer agents and were 
approved for use in the clinic and some were additionally found to sensitize can-
cer cells to common chemotherapeutics like cisplatin (Huang et al., 2013). How-
ever, under hypoxic, stressful conditions, cells are under a dominant checkpoint 
and so mTORC-1 should already be inhibited. Since we have shown that APP 
regulates the rate of protein synthesis (independently of mTORC-1) in hypoxic 
environment, we propose that APP can be considered as a potentially attractive 
therapeutic target in hypoxia-rich tumors.   
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STRATEGIES TO TARGET APP/AICD SIGNALING 
 
The phenomena observed upon APP depletion were reversed by overex-
pression of AICD. Unbound AICD is unstable and the factor Fe65 is thought to 
stabilize it (Kimberly et al., 2001). Nonetheless, Fe65 is only one of the many 
binding partners of AICD participating in AICD signaling and functions (Beckett, 
2012). The identification of the AICD binding partner mediating all the effects 
presented here is beyond the scope of this dissertation. This AICD binding part-
ner, once identified, could be targeted using a small molecule to disrupt its inter-
action with AICD. Using this strategy, we could reproduce the effects of APP ge-
netic ablation in hypoxic tumor tissue. Small molecules could be more effective 
than large inhibitors, like GSI, in reaching hypoxic areas of tumors, which are, by 
definition, distant from the vasculature.  
Cleavage of APP and AICD generation is reminiscent of Notch receptor 
cleavage and production of the NICD. The therapeutic efficacy of humanized 
monoclonal antibody mediated inhibition of Notch signaling is still under investi-
gation. These antibodies were shown to prevent Notch cleavage and diminish 
Notch mediated downstream signaling (Falk et al., 2012). Similar antibodies 
could be utilized to prevent cleavage of APP and AICD dependent signaling. Still, 
antibodies are large molecules and their delivery to distant, hypoxic tumor tissue 
could be problematic.  
Alternatively, novel signaling molecules downstream from APP and identi-
fied in this project, could be used as therapeutic targets, alone or in combination 
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with APP targeting. One of the most promising candidates is STYX, because it 
generates a phenotype that can be potentially detrimental to hypoxic NSCLC 
cells upon its inhibition.  
In conclusion, we have demonstrated a novel role for APP in moderating 
cell growth during G0/G1 transition. Disruption of APP signaling leads to necrotic 
cell death of hypoxic NSCLC cells. These findings have far-reaching implications 
in our understanding of hypoxic cancer cell biology and provide a novel therapeu-
tic target for the treatment of NSCLC.  
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